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The	  mosquito-­‐borne	  flavivirus	  infections	  Japanese	  encephalitis	  (JE)	  and	  dengue	  pose	  a	  considerable	   disease	   burden	   in	   the	   tropical	   and	   subtropical	   regions	   of	   the	   world.	  Sometimes	   these	   infections	  also	  affect	   international	   travelers	  visiting	  areas	  endemic	  for	   the	   diseases.	   This	   thesis	   addresses	   the	   prevention	   of	   Japanese	   encephalitis	   and	  diagnostics	   of	   dengue,	   with	   a	   focus	   on	   traveler’s	   health.	   The	  main	   aim	  was	   to	   find	  solutions	   to	   some	   practical	   clinical	   questions,	   and	   thus	   provide	   clinically	   important	  new	  data	  on	  travel-­‐associated	  flavivirus	  infections.	  The	   first	   three	   studies	   assessed	   the	   immunogenicity	   of	   two	   inactivated	   JE	  vaccines,	  the	  new	  Vero	  cell–derived	  (JE-­‐VC)	  and	  the	  traditional	  mouse	  brain–derived	  (JE-­‐MB)	  preparation,	  in	  120	  Finnish	  and	  Swedish	  adult	  travelers,	  by	  determining	  the	  pre-­‐	   and	   post-­‐vaccination	   titers	   of	   JE	   virus	   neutralizing	   antibodies	   with	   plaque-­‐reduction	  neutralization	  test	  (PRNT).	  A	  PRNT50	  titer	  ≥10	  was	  considered	  protective.	  Study	  I	  addressed	  the	  boosting	  capacity	  of	  the	  SA14-­‐14-­‐2–based	  JE-­‐VC	  vaccine	  in	   subjects	   previously	   primed	   with	   the	   Nakayama	   strain–based	   JE-­‐MB	   preparation.	  The	   response	   rates	   were	   91%	   after	   a	   homologous	   (JE-­‐MB)	   and	   95%-­‐98%	   after	   a	  heterologous	  booster	  dose	  (JE-­‐VC).	  Among	  those	  with	  no	  seroprotection	  at	  baseline,	  a	  higher	   proportion	   of	   JE-­‐MB–primed	   (100%)	   than	   non-­‐primed	   (40%)	   subjects	  seroconverted	   after	   a	   single	   JE-­‐VC	   dose.	   The	   data	   suggest	   that	   a	   single	   JE-­‐VC	   dose	  suffices	   for	   boosting	   JE-­‐MB	   immunity,	   and	   call	   for	   re-­‐evaluation	   of	   guidelines	  recommending	  two	  JE-­‐VC	  doses	  for	  JE-­‐MB–primed	  subjects.	  Study	  II	  demonstrated	  that	  both	  JE-­‐VC	  and	  JE-­‐MB	  elicit	  neutralizing	  antibodies,	  not	   only	   against	   the	   vaccine	   genotype,	   but	   also	   against	   heterologous	   JE	   virus	  genotypes.	  The	  seroprotection	  rates	  against	  the	  heterologous	  strains	  were	  93%-­‐97%	  after	   JE-­‐VC,	   and	   83%-­‐92%	   after	   JE-­‐MB	  primary	   series.	   The	   data	   imply	   that	   the	   two	  vaccines	   are	   expected	   to	   confer	   seroprotection	   against	   all	  major	   JE	   virus	   genotypes	  circulating.	  Study	  III	  evaluated	   long-­‐term	  seroprotection	  after	   JE-­‐VC	  primary	  and	  booster	  vaccinations.	   Two	   years	   after	   primary	   immunization,	   93%	   of	   vaccinees	   were	  seroprotected	  against	  the	  vaccine	  strain	  but	  only	  73%	  against	  the	  emerging	  genotype	  GI.	   JE-­‐MB–primed	   vaccinees	   were	   seroprotected	   against	   both	   vaccine	   (100%)	   and	  non-­‐vaccine	   (89%-­‐95%)	   genotype	   strains	   two	   years	   after	   the	   heterologous	   JE-­‐VC	  booster	   dose,	   further	   supporting	   the	   use	   of	   a	   single	   JE-­‐VC	   dose	   for	   boosting	   JE-­‐MB	  immunity.	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A	   total	   of	   26	   virus	   species	   of	   the	   genus	  Flavivirus,	   family	  Flaviviridae,	   are	   known	   to	  cause	  disease	   in	  humans1,2.	  While	  many	  of	   these	  viruses	  only	  have	  a	   limited	   impact	  worldwide,	  the	  virus	  group	  also	  includes	  pathogens	  of	  major	  global	  significance,	  such	  as	  dengue,	  Japanese	  encephalitis,	  tick-­‐borne	  encephalitis,	  West	  Nile,	  and	  yellow	  fever	  viruses.	  	  Recent	   decades	   have	   witnessed	   remarkable	   changes	   in	   the	   epidemiology	   of	  flaviviral	  diseases.	  One	  striking	  example	  is	  the	  recent	  introduction	  and	  rapid	  spread	  of	  West	  Nile	  virus,	  a	  close	  relative	  of	  Japanese	  encephalitis	  virus,	  in	  North	  America1.	  Over	  the	  past	  50	  years,	  the	  geographical	  distribution	  of	  dengue	  has	  expanded	  substantially,	  and	   today,	   more	   than	   100	   countries	   are	   affected3.	   In	   2010,	   autochthonous	   dengue	  cases	  were	  reported	   in	  Europe	   for	   the	   first	   time	  since	   the	  epidemic	   in	  Greece	   in	   the	  late	  1920s4-­‐7.	  In	  2012,	  a	  dengue	  epidemic	  with	  over	  2000	  cases	  occurred	  in	  Madeira8.	  Interestingly,	   genomic	   sequences	   of	   Japanese	   encephalitis	   virus	  were	   detected	   from	  mosquitoes	   in	  Italy	   in	  2012,	  suggesting	  for	  the	  first	  time	  introduction	  of	  the	  virus	  to	  Europe9.	   Thus	   far,	   no	   autochthonous	   cases	   of	   Japanese	   encephalitis	   have	   been	  reported.	  	  International	   travel	   has	   increased	   substantially	   in	   recent	   decades.	   In	   2012,	  over	   one	   billion	   people	   traveled	   outside	   their	   countries’	   borders,	  with	  Asia	   and	   the	  Pacific	  showing	  the	  greatest	  increase	  in	  international	  arrivals10.	  The	  growing	  numbers	  of	   international	   travel	   have	   also	   been	   reflected	   as	   an	   emergence	   of	   travel-­‐acquired	  dengue	   infections.	   Increasing	   mobility	   of	   humans	   thus	   exposes	   previously	   naïve	  populations	  to	  new	  pathogens.	  	  In	   addition	   to	   endemic	   data,	   study	   of	   flaviviral	   pathogens	   in	   non-­‐endemic	  populations	  is	  needed.	  Endemic	  and	  non-­‐endemic	  populations	  differ	  in	  many	  essential	  background	  characteristics,	  such	  as	  the	  average	  age	  at	  the	  time	  of	  primary	  infection,	  genetic	   background,	   and	   pre-­‐existing	   immunity	   to	   other	   flaviviruses	   –	   all	   of	   these	  factors	  may	  significantly	  affect	  the	  outcome	  of	  the	  infection11.	  This	   thesis	   addresses	   two	   globally	   important	   flavivirus	   infections,	   Japanese	  encephalitis	   and	   dengue,	   with	   a	   focus	   on	   traveler’s	   health.	   Prevention	   of	   Japanese	  encephalitis	  by	  vaccination	  is	  a	  frequent	  clinical	  question	  at	  pre-­‐travel	  appointments	  among	   travelers	   heading	   to	   Asia,	   while	   dengue	   is	   one	   of	   the	   leading	   post-­‐travel	  challenges	  in	  ill	  travelers	  returning	  from	  the	  tropics	  and	  subtropics	  around	  the	  world.	  Of	  the	  four	  original	  studies,	  three	  explore	  Japanese	  encephalitis	  vaccine	  immunity,	  and	  one	   focuses	   on	   the	   diagnostics	   of	   dengue	   infections	   in	   travelers	   from	   Northern	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1. REVIEW OF THE LITERATURE 
1.1	  Brief	  introduction	  to	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Table	  1.	  Flavivirus	  species	  pathogenic	  to	  human	  (adapted	  from1,2)	  	  
	  	   Geographic	  distribution	   Clinical	  manifestation	  
TICK-­‐BORNE	   	  	   	  	  
	  	  	  	  	  Mammalian	  tick-­‐borne	  virus	  group	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  Kyasanur	  Forest	  disease	  virus	   India,	  Arabian	  Peninsula?	   hemorrhagic	  fever	  
	  	  	  	  	  	  	  	  	  	  	  	  Langat	  virus	   Malaysia,	  Thailand,	  Siberia	   encephalitis	  
	  	  	  	  	  	  	  	  	  	  	  	  Louping	  ill	  virus	   UK,	  Ireland	   encephalitis	  
	  	  	  	  	  	  	  	  	  	  	  	  Omsk	  hemorrhagic	  fever	  virus	   Western	  Siberia	   hemorrhagic	  fever	  
	  	  	  	  	  	  	  	  	  	  	  	  Powassan	  virus	   Russia,	  USA,	  Canada	   encephalitis	  
	  	  	  	  	  	  	  	  	  	  	  	  Tick-­‐borne	  encephalitis	  virus	   Europe,	  Asia	   encephalitis	  
MOSQUITO-­‐BORNE	   	  	   	  	  
	  	  	  	  	  Aroa	  virus	  group	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  Bussuquara	  virus	   Brazil	   fever	  
	  	  	  	  	  Dengue	  virus	  group	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1.2	  Japanese	  encephalitis	  
1.2.1	  Etiology	  
Japanese	  encephalitis	  virus	  (JEV),	  the	  causative	  agent	  of	  Japanese	  encephalitis	  (JE),	  is	  a	  member	   of	   the	   Japanese	   encephalitis	   virus	   group	   in	   genus	   Flavivirus,	   family	  
Flaviviridae.	  Other	  species	  of	  the	  group	  include	  the	  widely	  dispersed	  West	  Nile	  virus,	  St	  
Louis	   encephalitis	   virus	   in	   the	  Americas,	  Murray	  Valley	   encephalitis	   virus	   in	  Australia	  and	  New	  Guinea,	  Cacipacore	  virus	  in	  South	  America,	  Usutu	  virus	  in	  Europe	  and	  Africa,	  as	  well	  as	  Koutango	  and	  Yaounde	  viruses	  in	  Africa2,12.	  	  	  
	  
Figure	  2.	  The	  geographical	  distribution	  of	  four	  major	  members	  of	  the	  Japanese	  encephalitis	  virus	  
group:	   Japanese	   encephalitis	   virus	   (JEV),	   Murray	   Valley	   encephalitis	   virus	   (MVEV),	   St	   Louis	  
encephalitis	   virus	   (SLEV),	   and	  West	   Nile	   virus	   (WNV).	   Reprinted	   by	   permission	   from	  Macmillan	  






1.2.2	  Japanese	  encephalitis	  virus	  genotypes	  
JE	   viruses	   are	   divided	   into	   five	   phylogenetically	   distinct	   genotypes	   (GI-­‐GV)13.	   The	  relationships	  between	  different	   JEV	   strains	  were	   first	   established	  by	  analyses	  based	  on	   limited	   sequences	   of	   the	   C/prM	   gene	   region,	   while	   more	   recent	   studies	   have	  utilized	   the	   E	   gene	   or	   full-­‐length	   genomic	   sequences	   for	   phylogenetic	  investigations12,14.	  	  The	   most	   divergent	   JEV	   genotypes,	   GIV	   and	   GV,	   are	   regarded	   the	   oldest	  lineages13.	  There	  is	  no	  evidence	  on	  these	  genotypes	  causing	  human	  disease	  at	  present.	  Only	   three	   strains	  of	  GV	  have	  ever	  been	   found:	   the	   first	   one	   (Muar	   strain)	   from	   the	  brain	  of	  a	  Malaysian	  patient	  in	  1952,	  and	  the	  two	  others	  from	  mosquito	  pools	  in	  China	  in	  2009	  (XZ0934	  strain),	  and	  in	  South	  Korea	  in	  2010	  (10-­‐1827	  strain)15,16.	  As	  for	  GIV,	  five	   strains	   of	   this	   type	   have	   been	   identified	   (JKT-­‐6468,	   JKT-­‐7003,	   JKT-­‐7887,	   JKT-­‐8442,	  JKT-­‐9092),	  all	  isolated	  in	  Indonesia	  (in	  Java,	  Bali,	  and	  Flores)	  in	  the	  beginning	  of	  the	  1980s.	  All	  of	   these	  GIV	   isolates	  originated	   in	  mosquito	  pools,	  and	  their	  ability	   to	  cause	  human	  disease	  remains	  unproven17.	  Of	  the	  three	  more	  recent	  JEV	  genotypes,	  reports	  on	  GII	  isolates	  are	  the	  rarest.	  The	  earliest	  known	  GII	  isolate	  (Bennett	  strain)	  was	  identified	  in	  Korea	  before	  the	  year	  195118.	   Between	   1970	   and	   1999,	   several	   GII	   strains	   were	   isolated	   in	   Southern	  Thailand,	  Malaysia,	  Indonesia,	  Papua	  New	  Guinea,	  and	  Northern	  Australia12,19-­‐21.	  In	  the	  21st	  century,	  no	  reports	  of	  GII	  encephalitis	  have	  been	  published.	  While	  the	  clinical	  importance	  of	  GII,	  GIV,	  and	  GV	  appears	  minor	  at	  present,	  the	  remaining	   two	   genotypes,	   GI	   and	   GIII,	   have	   been	   associated	   with	   recent	   JE	  outbreaks22-­‐25.	  	  Since	   the	   first	   isolation	   of	   a	   JE	   virus	   (Nakayama	   strain,	   GIII)	   in	   1935,	   strains	  belonging	  to	  GIII	  have	  been	  recognized	  as	  a	  major	  cause	  of	  clinical	  encephalitis.	  Until	  the	  latter	  part	  of	  the	  20th	  century,	  GIII	  was	  the	  dominant	  genotype	  circulating	  in	  large	  areas	  of	  Asia12.	  Since	  then,	  however,	  GI	  has	  been	  emerging,	  and	  many	  Asian	  countries	  have	  reported	  the	  replacement	  of	  GIII	  by	  GI	  strains12,14.	  The	  genotype	  shift	  from	  GIII	  to	  GI	  occurred	  in	  Japan	  and	  South	  Korea	  in	  the	  early	  1990s26-­‐30,	  in	  Thailand	  and	  Vietnam	  by	  the	  beginning	  of	  the	  21st	  century31-­‐33,	  and	  in	  Taiwan	  around	  the	  year	  200934-­‐36.	  In	  2000,	  the	  appearance	  of	  GI	  was	  also	  demonstrated	  in	  the	  Torres	  Strait	  of	  Australia37.	  In	  China	  and	  India,	  both	  GI	  and	  GIII	  co-­‐circulate23-­‐25,38-­‐41.	  Despite	   existence	   of	   multiple	   genotypes,	   it	   is	   believed	   that	   all	   JEV	   strains	  belong	   to	   a	   single	   serotype.	  An	   analysis	   of	   complete	  E	   gene	   regions	  of	   different	   JEV	  strains	  showed	  that	  the	  divergence	  between	  strains	  was	  up	  to	  12%	  (at	  the	  amino	  acid	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level),	  which	   is	   less	   than	   the	  minimum	  difference	   between	   established	   serotypes	   of	  other	  positive-­‐strand	  RNA	  viruses	  studied;	  polio	  (18%)	  and	  dengue	  (22%)42.	  
1.2.3	  Transmission	  
Pigs	   and	   ardeid	   birds	   are	   the	   main	   vertebrate	   hosts	   of	   JEV43.	   Virus	   transmission	  occurs	   principally	   through	   Culex	  mosquitoes,	   of	   which	   Cx.	   tritaeniorhynchus	   is	   the	  main	   vector	   species.	   It	   breeds	   in	   water	   pools	   and	   flooded	   rice	   fields,	   and	   feeds	  outdoors	   at	   night	   time43.	   Important	   secondary	   vectors	   include,	   for	   instance,	   Cx.	  
gelidus,	  Cx.	  fuscocephala,	  and	  Cx.	  annulirostris44.	  Humans	  acquire	  the	  virus	  when	  bitten	  by	  an	  infected	  vector	  mosquito.	  In	  rare	  occasions,	   transplacental	   transmission	   from	   mother	   to	   fetus	   has	   been	   described45.	  Humans	  are	  only	  incidental	  and	  dead-­‐end	  hosts	  of	  JEV;	  they	  do	  not	  contribute	  to	  the	  natural	  transmission	  cycle	  due	  to	  low	  and	  transient	  viremia46.	  
1.2.4	  Epidemiology	  
According	  to	  current	  data,	  a	  total	  of	  twenty-­‐five	  countries	  have	  areas	  with	  risk	  of	  JEV	  transmission47.	  The	  affected	  countries	   include	  Australia,	  Bangladesh,	  Bhutan,	  Brunei	  Darussalam,	   Burma	   (Myanmar),	   Cambodia,	   China,	   India,	   Indonesia,	   Japan,	   Laos,	  Malaysia,	   Nepal,	   North	   Korea,	   Pakistan,	   Papua	   New	   Guinea,	   the	   Philippines,	   Russia,	  Singapore,	  South	  Korea,	  Sri	  Lanka,	  Taiwan,	  Thailand,	  Timor-­‐Leste,	  and	  Vietnam.	  JE	   is	   predominantly	   a	   rural	   disease,	   yet	   cases	   may	   also	   occur	   in	   peri-­‐urban	  areas	   where	   the	   elements	   required	   for	   the	   transmission	   cycle	   are	   available.	   Two	  epidemiological	   patterns	   are	   characteristic	   for	   the	   disease;	   seasonal	   summer	  epidemics	   in	   temperate	   regions,	   and	   a	   year-­‐round	   transmission	   with	   rainy	   season	  epidemics	  in	  tropical	  areas12.	  	  Reliable	  data	  on	  the	  incidence	  of	  JE	  are	  lacking.	  In	  rural	  hyperenzootic	  settings,	  almost	   all	   the	   population	   is	   exposed	   to	   the	   virus	   by	   early	   adulthood48.	   The	   vast	  majority	   of	   human	   JEV	   infections	   are	   asymptomatic,	   and	   only	   around	   0.1%-­‐4%	   of	  infected	   persons	   develop	   a	   clinical	   illness46.	   According	   to	   estimates,	   JEV	   causes	  approximately	  68,000	  clinical	  cases	  each	  year,	  of	  which	  around	  14,300-­‐27,200	  lead	  to	  long-­‐term	  disability	   and	  13,600-­‐20,400	   to	  death49.	   JE	   is	   largely	   a	   childhood	  disease;	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approximately	  75%	  of	  the	  cases	  affect	  children	  below	  15	  years	  of	  age49.	  A	  second	  peak	  in	  incidence	  is	  seen	  in	  the	  elderly50,	  probably	  due	  to	  waning	  immunity.	  
1.2.5	  Clinical	  features	  
1.2.5.1	  Symptoms	  
JEV	   has	   an	   incubation	   period	   of	   5	   to	   15	   days.	   A	   non-­‐specific	   viral	   prodrome	   often	  precedes	   the	   neurologic	   illness	   which	   may	   involve	   the	   brain	   parenchyma	  (encephalitis),	  meninges	  (aseptic	  meningitis),	  or	  spinal	  cord	  (myelitis)50.	  A	  typical	  JEV	  meningoencephalitis	   presents	   with	   fever,	   vomiting,	   headache,	   nuchal	   rigidity,	   focal	  neurologic	  signs,	  and	  a	  reduced	  level	  of	  consciousness.	  Seizures	  are	  more	  frequent	  in	  children	  than	  in	  adults46.	  Motor	  weakness	  and	  movement	  disorders	  are	  common.	  The	  classic	   Parkinsonian	   syndrome	   associated	   with	   JE	   is	   characterized	   by	   dull	   facies,	  cogwheel	  rigidity,	  and	  tremor.	  	  
1.2.5.2	  Laboratory	  and	  radiological	  findings	  
Routine	  blood	   laboratory	   findings	  may	   include	  mild	   leukocytosis	  and	  hyponatremia.	  Cerebrospinal	   fluid	   (CSF)	  analysis	   typically	   reveals	  a	  pleocytosis	  of	  10	   to	  500	  /mm3	  with	  lymphocytes	  predominating,	  a	  normal	  or	  slightly	  elevated	  protein	  concentration,	  and	  normal	  glucose	  levels.	  The	  CSF	  opening	  pressure	  may	  be	  elevated50.	  	  When	   exploring	   the	   radiological	   findings	   in	   JE,	   magnetic	   resonance	   imaging	  (MRI)	  is	  more	  sensitive	  than	  computed	  tomography	  (CT)51.	  Bilateral	  thalamic	  lesions	  are	   characteristic51-­‐53.	   Typical	   findings	   may	   include	   lesions	   in	   the	   basal	   ganglia,	  midbrain,	   cerebellum,	   pons,	   and	   cerebral	   cortex51-­‐53.	   Hemorrhagic	   lesions	   are	  common52,53.	  
1.2.6	  Microbiological	  diagnostics	  
In	   clinical	   settings,	   the	  microbiological	   diagnostics	   of	   JE	  mostly	   relies	   on	   serological	  methods.	   Demonstration	   of	   JEV-­‐specific	   antibody	   in	   CSF	   by	   IgM	   capture	   enzyme-­‐linked	   immunosorbent	   assay	   (ELISA)	   is	   usually	   regarded	   as	   confirmatory	   for	   the	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diagnosis54,55.	   In	   many	   endemic	   areas,	   the	   possibilities	   to	   obtain	   a	   laboratory-­‐confirmed	   diagnosis	   are	   limited.	   As	   lumbar	   puncture	   is	   not	   feasible	   in	   all	   settings,	  serum	   samples	   are	   also	   used	   for	   detection	   of	   virus-­‐specific	   IgM	   antibodies,	   even	  though	  the	  positive	  predictive	  value	  of	  the	  IgM	  capture	  ELISA	  is	  lower	  in	  serum	  than	  in	   CSF.	   If	   the	   early	   serum	   sample	   proves	   negative	   for	   anti-­‐JEV	   IgM	   antibodies,	  assessment	  of	  a	  second	  sample	  at	  around	  the	  10th	  day	  of	  illness	  is	  recommended54.	  	  Due	   to	   antigenic	   similarities	   among	   flaviviruses,	   cross-­‐reactive	   responses	   are	  often	   seen	   in	   the	   serologic	   assays.	   This	   should	   be	   taken	   into	   account	   in	   the	  interpretation	  of	   serologic	   tests,	   as	  a	  positive	   test	   result	  may	  not	  always	  specify	   the	  etiologic	  agent.	  In	  JEV	  endemic	  areas,	  other	  relevant	  flaviviruses	  include,	  for	  instance,	  dengue	   and	   West	   Nile	   viruses.	   In	   temperate	   areas	   of	   Europe	   and	   Asia,	   immune	  responses	  to	  tick-­‐borne	  encephalitis	  virus	  should	  be	  considered.	  Similarly,	  the	  history	  of	  flavivirus	  vaccinations	  may	  be	  of	  relevance.	  Notably,	  because	  of	  the	  shortness	  and	  low	  level	  of	  JEV	  viremia,	  efforts	  to	  isolate	  the	  virus	  or	  detect	  its	  genome	  in	  serum	  or	  CSF	  usually	  fail54.	  	  The	   differential	   diagnosis	   of	   JE	   includes	   other	   viral	   and	   flaviviral	  encephalitides,	   bacterial,	   fungal,	   and	   parasitic	   infections,	   as	   well	   as	   non-­‐infectious	  etiologies56.	  Special	  attention	  should	  be	  paid	  to	  central	  nervous	  system	  infections	  for	  which	   specific	   treatment	   are	   available,	   such	   as	   Herpes	   simplex	   virus	   infections,	  bacterial	  meningitis,	  and	  cerebral	  malaria.	  
1.2.7	  Treatment	  and	  prognosis	  
While	   infection	  with	   JEV	   is	   usually	   asymptomatic,	   clinical	   cases	   often	  have	   a	   severe	  outcome.	  Currently,	  no	  specific	  therapy	  exists	  for	  JE.	  Treatment	  consists	  of	  supportive	  care,	   and	   management	   of	   infection	   complications,	   including	   seizures,	   raised	  intracranial	  pressure,	  and	  secondary	  infections.	  	  Reported	  case-­‐fatality	  rates	  vary	  between	  8%	  and	  33%57-­‐60,	  and	  approximately	  half	  of	  the	  survivors	  suffer	  from	  persistent	  sequelae,	  such	  as	  motor	  deficits,	  seizures,	  cognitive	   impairment	   of	   varying	   severity,	   as	   well	   as	   changes	   in	   behavior	   and	  personality59,61,62.	  Various	  predictors	  of	  poor	  outcome	  have	  been	  reported,	   including	  female	   sex,	   advanced	   age,	   successful	   virus	   isolation	   from	   CSF,	   low	   Glasgow	   coma	  score,	   seizures,	   presence	   of	   focal	   neurological	   deficits,	   and	   a	   prolonged	   illness	  course57,59-­‐61,63.	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1.2.8	  Japanese	  encephalitis	  in	  travelers	  







Table	  2.	  Background	  characteristics	  of	  the	  travel-­‐associated	  JE	  cases,	  1973-­‐2011.	  	  
Age,	  sex,	  and	  travel	  history	  of	  the	  patients.	  
	  	   median	   range	  
Age	   35	   (1-­‐91)	  
	  	   %	   n	  
Sex	   	  	   	  	  
	  	  	  	  	  	  Male	   54	  %	   (31/57)	  
	  	  	  	  	  	  Female	   46	  %	   (26/57)	  
Duration	  of	  travel	   	   	  
	  	  	  	  	  	  <4	  weeks	   37	  %	   (15/41)	  
	  	  	  	  	  	  ≥4	  weeks	   63	  %	   (26/41)	  
Travel	  destination	   	  	   	  	  
	  	  	  	  	  	  Thailand	   37	  %	   (21/57)	  
	  	  	  	  	  	  Indonesia	   16	  %	   (9/57)	  
	  	  	  	  	  	  China	   12	  %	   (7/57)	  
	  	  	  	  	  	  the	  Philippines	   12	  %	   (7/57)	  
	  	  	  	  	  	  Japan	   7	  %	   (4/57)	  
	  	  	  	  	  	  Vietnam	   5	  %	   (3/57)	  
	  	  	  	  	  	  Cambodia	   2	  %	   (1/57)	  
	  	  	  	  	  	  Papua	  New	  Guinea	   2	  %	   (1/57)	  
	  	  	  	  	  	  Malaysia	   2	  %	   (1/57)	  
	  	  	  	  	  	  Singapore	   2	  %	   (1/57)	  
	  	  	  	  	  	  Hong	  Kong	   2	  %	   (1/57)	  




Several	  interventions	  have	  been	  proposed	  for	  reducing	  the	  incidence	  of	  JE	  in	  humans,	  including	   control	   of	  mosquito	   and	  pig	   populations,	   personal	   protective	  measures	   to	  avoid	  mosquito	  bites,	  and	  so	  far	  the	  most	  effective	  means,	  human	  immunization77.	  	  The	   current	   strategies	   to	   control	   vector	  mosquito	   populations	   in	   rural	   areas	  have	   proven	   insufficient77.	   Biological	   control	   agents,	   such	   as	   larvicidal	   bacteria,	  larvivorous	  fish,	  or	  different	  natural	  products	  have	  been	  proposed	  as	  environmental-­‐friendly	   alternatives	   for	   chemical	   insecticides78.	   Alternate	   wet	   and	   dry	   irrigation,	   a	  vector	   control	   approach	   of	   a	   different	   type,	   has	   shown	   to	   decrease	   Cx.	  
tritaeniorhynchus	  populations	  in	  rice	  fields,	  while	  simultaneously	  increasing	  the	  crop	  yield	   and	   decreasing	   water	   consumption78.	   As	   for	   control	   of	   pig	   populations,	  vaccination	   of	   swines	   appears	   impractical	   and	   ineffective	   in	   preventing	   human	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disease,	  whereas	  relocation	  of	  domestic	  pigs	  distant	  from	  human	  habitats	  might	  have	  a	  positive	  effect	  in	  reducing	  JE	  incidence44.	  Personal	  protective	  measures,	  besides	  active	  immunization,	  focus	  on	  reducing	  the	  risk	  of	  vector	  exposure	  by	  using	  mosquito	  repellents	  and	  protective	  clothing,	  by	  avoiding	  outdoor	  activities	  in	  the	  evening,	  and	  by	  sleeping	  in	  screened	  rooms	  or	  under	  permethrin-­‐impregnated	  mosquito	  bed	  nets79.	  These	  interventions	  provide,	  however,	  only	  a	  limited	  solution.	  
1.2.10	  Active	  immunization	  against	  Japanese	  encephalitis	  
Active	   immunization	  of	  humans	   is	   currently	   considered	   the	  most	  effective	  means	   to	  reduce	   JE	   incidence77.	  After	   implementation	  of	  routine	  childhood	  vaccinations	   in	   the	  late	   1960s	   and	   1970s,	   several	   endemic	   countries	   have	   experienced	   a	   remarkable	  decline	  in	  disease	  incidence48.	  Humans	  only	  being	  dead-­‐end	  hosts	  of	  the	  virus,	  the	  JE	  vaccines	  do	  not	  confer	  herd	   immunity.	  Moreover,	  as	  several	  host	  and	  vector	  species	  are	  involved,	  complete	  eradication	  of	  the	  virus	  is	  unlikely.	  
1.2.10.1	  Vaccination	  of	  endemic	  populations	  




1.2.10.2	  Vaccination	  of	  travelers	  




1.2.11	  Assessment	  of	  Japanese	  encephalitis	  vaccine	  efficacy	  
Vaccine	   efficacy	   is	   ideally	   assessed	   through	   randomized,	   double-­‐blind,	   placebo-­‐controlled	  trials	  with	  reduction	  in	  disease	  incidence	  as	  the	  primary	  endpoint.	  Having	  internationally	   registered	   JE	   vaccines	   available,	   acquisition	   of	   direct	   efficacy	   data	  through	   placebo-­‐controlled	   trials	   is	   considered	   unethical.	   Comparator	   vaccine–controlled	  trials,	  on	  the	  other	  hand,	  are	  too	   laborious	  to	  conduct	  since	  the	  relatively	  low	   incidence	   of	   the	   disease	  would	   imply	   extremely	   large	   study	   populations.	   As	   an	  alternative	   for	   efficacy	   studies,	   case-­‐control	   studies	   can	   be	   used	   to	   assess	   vaccine	  effectiveness,	   i.e.	   the	   ability	   of	   the	   vaccine	   to	   reduce	   disease	   incidence	   in	   routine	  circumstances.	   These	   studies	   require	   a	   significantly	   smaller	   study	   population	   than	  efficacy	  trials;	  however,	  the	  major	  challenge	  with	  case-­‐control	  studies	  is	  to	  ensure	  that	  the	   vaccinated	   and	   unvaccinated	   study	   participants	   are	   alike	   in	   all	   relevant	  characteristics	   other	   than	   vaccination.	   Due	   to	   the	   above	   mentioned	   limitations,	   JE	  vaccine	   studies,	   similarly	   to	   several	   other	   virus	   vaccine	   studies,	   have	   adopted	  immunological	  endpoint	  measurements	  as	  surrogate	  markers	  of	  protection86.	  	  Antibodies	  represent	  an	  important	  part	  of	  the	  protective	  immunity	  against	  JEV	  and	   other	   flavivirus	   infections87.	   According	   to	   early	   data	   with	   limited	   numbers	   of	  subjects,	   laboratory	  workers	  who	   passively	   received	   JEV	   antibodies	   after	   accidental	  exposure	   to	   the	  virus	  did	  not	  develop	  a	   clinical	  disease88.	   In	  animal	  models,	  passive	  transfer	   of	   virus-­‐specific	   antibodies	   or	   immune	   sera	   confers	   protection	   against	   a	  subsequent	   challenge	  with	   JEV89-­‐92.	   Moreover,	   the	   level	   of	   protection	   has	   shown	   to	  correlate	  positively	  with	  the	  input	  antibody	  titer91.	  The	  JEV	  E	  protein	  is	  considered	  to	  be	  a	  major	  target	  of	  the	  antibody	  response93.	  	  A	  WHO	  expert	  panel	  recommends	  determination	  of	  neutralizing	  antibodies	  by	  the	  plaque-­‐reduction	  neutralization	  test	  (PRNT)	  for	  assessing	  the	  immunogenicity	  of	  JE	   vaccines86.	   A	   PRNT50	   titer	   of	   ≥10	   is	   accepted	   as	   an	   indicator	   of	   protective	  immunity86.	  	  PRNT	   is	   a	   functional	   assay	   measuring	   virus	   neutralization	   in	   vitro.	   It	   is	  regarded	  the	  most	  virus-­‐specific	  test	  among	  all	  the	  serological	  flaviviral	  tests94.	  Figure	  3	  illustrates	  the	  principle	  of	  the	  test.	  In	  order	  to	  determine	  JEV-­‐neutralizing	  antibodies	  in	  the	  test	  serum,	  a	  predetermined	  amount	  of	  virus	  is	  mixed	  with	  the	  heat-­‐inactivated	  serum	   sample,	   and,	   after	   incubation,	   the	   serum-­‐virus	   mixture	   is	   added	   to	   virus-­‐susceptible	   cells.	   If	   the	   serum	   contained	   neutralizing	   antibodies,	   virus-­‐antibody	  interactions	  occur	  and	  the	  amount	  of	   infectious	  virus	   is	  reduced,	  as	   indicated	  by	  the	  formation	   of	   fewer	   viral	   plaques	   in	   a	   cell	   monolayer.	   The	   number	   of	   plaques	   is	  compared	   to	   that	   observed	   after	   a	   virus-­‐only	   inoculation,	   and	   the	   test	   serum	   titer	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resulting	   in	   a	   given	   reduction	   in	   plaque	   number	   is	   calculated.	   A	   PRNT	   titer	   is	   the	  reciprocal	   of	   the	   serum	   dilution	   that	   reduces	   the	   virus	   plaque	   count	   by	   a	   certain	  percentage	   compared	   to	   the	   virus-­‐only	   controls.	   The	   PRNT	   protocols	   may	   vary	   in	  many	  essential	  respects,	  including	  the	  choice	  of	  the	  test	  virus	  strain,	  cell	  line,	  and	  cell	  culture	   conditions,	   as	   well	   as	   the	   percentage	   of	   plaque	   reduction	   required86.	   The	  differing	   protocols	   may	   not	   be	   readily	   comparable,	   which	   should	   be	   taken	   into	  account	   in	   the	   interpretation	   and	   comparison	   of	   results	   derived	   with	   various	  protocols.	  
	  
	  
Figure	  3.	  The	  principle	  of	   the	  plaque-­‐reduction	  neutralization	  test	   (PRNT).	  Serial	  dilutions	  of	   test	  
sera	  are	  mixed	  with	  a	  predetermined	  amount	  of	  virus.	  The	  serum-­‐virus	  mixture	  is	  incubated.	  If	  the	  
serum	   contained	   test	   virus–neutralizing	   antibodies,	   virus-­‐antibody	   interactions	   occur	   and	   the	  
amount	  of	  infectious	  virus	  is	  reduced.	  The	  serum-­‐virus	  mixture	  is	  added	  to	  virus-­‐susceptible	  cells.	  
After	   incubation,	  the	  numbers	  of	  plaques	  are	  counted.	  A	  PRNT50	  titer	   is	  the	  reciprocal	  of	  the	  test	  




1.2.12	  Japanese	  encephalitis	  vaccines	  




1.2.12.1	  Inactivated	  mouse	  brain–derived	  Nakayama-­based	  vaccine	  
The	  first	  versions	  of	  the	  inactivated,	  mouse	  brain–derived	  JE	  vaccines	  were	  developed	  as	   early	   as	   the	   1930s48.	   Later,	   the	   production	   was	   refined,	   and	   more	   purified	  preparations	   became	   available.	   In	   the	   current	   manufacturing	   process,	   the	   mouse	  brain–propagated	  vaccine	  virus	  is	  inactivated	  with	  formaldehyde,	  purified,	  stabilized	  with	   gelatin	   and	   sodium	   glutamate,	   and	   preserved	  with	   thiomersal.	   Before	   use,	   the	  freeze-­‐dried	  product	   is	  reconstituted	  with	  sterile	  water.	  The	  vaccine	   is	  administered	  subcutaneously.	  The	  following	  sections	  discuss	  the	  immunogenicity	  and	  safety	  of	  the	  internationally	  available	  Nakayama	  strain–based	  preparation	  (JE-­‐MB).	  
Immunogenicity	  and	  protective	  efficacy	  
In	   endemic	   areas,	   the	   JE-­‐MB	   vaccines	   are	   usually	   administered	   in	   two	  doses	   one	   to	  four	  weeks	  apart,	  with	  subsequent	  boosters	  at	  one	  to	  three	  years’	  intervals.	  Efficacy	  of	  the	   two-­‐dose	   primary	   schedule	   was	   demonstrated	   in	   a	   large,	   placebo-­‐controlled,	  randomized	  trial	  in	  Thai	  children	  in	  the	  1980s95.	  The	  study	  showed	  an	  efficacy	  of	  91%	  (95%	  CI:	  54-­‐98)	  against	  symptomatic	  JE	  both	  for	  a	  monovalent	  (Nakayama	  strain)	  and	  a	   bivalent	   (Nakayama	   and	   Beijing-­‐1	   strain)	   preparation.	   Furthermore,	   the	   trial	  provided	  some	  evidence	  on	  the	  vaccines	  reducing	  the	  severity	  of	  subsequent	  dengue	  infections.	  In	   non-­‐endemic	   populations,	   no	   efficacy	   trials	   have	   been	   conducted.	   The	  immunogenicity	  studies	  conducted	  in	  non-­‐endemic	  adult	  populations	  suggest	  that	  the	  seroprotection	   provided	   by	   a	   two-­‐dose	   primary	   schedule	   might	   be	   insufficient	   for	  persons	  with	  less	  natural	  exposure	  to	  circulating	  flaviviruses.	  In	  one	  US	  study,	  77%	  of	  vaccinees	  seroconverted	  after	  two	  doses,	  and	  only	  29%	  were	  seroprotected	  six	  to	  12	  months	  later96.	  In	  another	  US	  study,	  the	  seroprotection	  rate	  was	  80%	  at	  two	  months,	  and	  33%	  at	   six	  months	   following	   a	   two-­‐dose	  primary	   series97.	   By	   contrast,	   a	   three-­‐dose	   primary	   regimen	   has	   been	   shown	   to	   elicit	   neutralizing	   antibodies	   in	   91%	   to	  100%	  of	  vaccinees98-­‐100,	  and	  consequently,	  three	  doses,	  given	  usually	  on	  days	  0,	  7,	  and	  30,	  are	  recommended	  for	  primary	  immunization	  of	  non-­‐endemic	  populations82.	  Data	   on	   the	   duration	   of	   JE-­‐MB–induced	   immune	   protection	   are	   scarce.	   One	  study	   in	  293	  US	   laboratory	  workers	   showed	  a	  50%	  seroprotection	   rate	   around	   two	  years	  after	  a	  three-­‐dose	  primary	  series100,	  while	  a	  small-­‐scale	  follow-­‐up	  study	  in	  17	  US	  soldiers	  showed	  protective	  levels	  of	  neutralizing	  antibodies	  up	  to	  three	  years	  after	  a	  three-­‐dose	  primary	  series	   in	   the	  majority	   (94%)	  of	   subjects101.	  Among	  219	  children	  and	   adults	   living	   in	   Badu	   island	   (Torres	   Strait,	   Australia),	   only	   70	   (32%)	   were	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seroprotected	  around	  three	  years	  after	  primary	  or	  booster	  vaccination102.	  Of	  note,	  in	  that	   study,	   the	  neutralizing	  antibody	  responses	  were	  assessed	  by	  a	  PRNT80	  protocol	  which	  requires	  a	  greater	  reduction	  (80%)	  in	  plaque	  count	  than	  the	  more	  widely	  used	  PRNT50.	  
Safety	  
Local	  side	  effects,	  such	  as	  soreness	  or	  redness	  at	  the	  injection	  site,	  have	  usually	  been	  reported	  in	  around	  20%	  of	  vaccine	  recipients96,97,99,103.	  Systemic	  adverse	  events	  (AE)	  occur	   in	   approximately	   10%	   to	   40%	   of	   vaccinees,	   and	   may	   include,	   for	   instance,	  headache,	  fatigue,	  myalgia,	  influenza-­‐like	  illness,	  or	  nausea96,97,99,103,104.	  	  The	   mouse	   brain–derived	   JE	   vaccines	   have	   been	   associated	   with	  hypersensitivity	   reactions,	   including	  generalized	  urticaria,	  angioedema,	  and	   in	  a	   few	  cases,	   anaphylaxis105-­‐109.	   In	   addition,	   sporadic	   cases	   of	   neurologic	   complications	  temporally	   related	   to	   vaccination	   have	   been	   reported109-­‐112.	   In	   1999-­‐2009,	   the	   U.S.	  surveillance	   system	   for	   vaccine	   adverse	   events	   received	   23	   reports	   of	   serious	   AE:s,	  corresponding	  to	  a	  reporting	  rate	  of	  1.8	  serious	  AE:s	  per	  100,000	  doses	  distributed113.	  The	   reported	   cases	   included,	   among	   others,	   one	   fatality	   (sudden	   death	   after	   JE-­‐MB	  and	   typhoid	   vaccinations	   in	   a	   male	   soldier	   using	   over-­‐the-­‐counter	  pseudoephedrine114),	  nine	  hypersensitivity	  events,	  and	  three	  neurologic	  events	  (Bell’s	  palsy,	  generalized	  weakness,	  and	  ataxia)113.	  
1.2.12.2	  Inactivated	  Vero	  cell–derived	  SA14-­14-­2–based	  vaccine	  
The	   internationally	   available	   inactivated,	   Vero	   cell–derived	   JE	   vaccine	   (JE-­‐VC),	   is	  based	  on	  an	  attenuated	  JEV	  strain,	  SA14-­‐14-­‐2.	  The	  vaccine	  virus	  is	  grown	  in	  Vero	  cells,	  purified,	   inactivated	   with	   formaldehyde,	   and	   adsorbed	   to	   aluminum	   hydroxide	  adjuvant.	  A	  single	  dose	  contains	  6	  µg	  of	  the	  virus115.	  	  
Immunogenicity	  
The	   primary	   vaccination	   series	   with	   JE-­‐VC	   consists	   of	   two	   intramuscular	   injections	  into	   the	   deltoid	   muscle	   on	   days	   0	   and	   28115.	   The	   immunogenicity	   of	   the	   primary	  regimen	  was	  demonstrated	  in	  a	  non-­‐inferiority,	  randomized	  controlled	  trial	  in	  which	  98%	  of	  the	  adult	  subjects	  developed	  neutralizing	  antibodies	  against	  the	  vaccine	  strain	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by	  day	  56103.	  A	  late	  completion	  of	  the	  primary	  series	  seems	  beneficial:	  extending	  the	  dosing	  interval	  to	  11	  months	  led	  to	  even	  higher	  titers	  of	  neutralizing	  antibodies	  and	  a	  more	  long-­‐lasting	  protection	  than	  the	  standard	  0/28	  regimen116.	  Immunogenicity	  of	  a	  single-­‐dose	  primary	  regimen	  has	  proven	  insufficient,	  with	  seroprotection	  rates	  of	  only	  26%	  and	  41%	  two	  months	  after	  a	  single	  6µg	  or	  12	  µg	  dose	  of	  JE-­‐VC117.	  Concomitant	  administration	  of	   JE-­‐VC	  and	  an	   inactivated	  hepatitis	  A	  vaccine	   (Havrix1440)	  did	  not	  reduce	  the	  immunogenicity	  of	  either	  preparation118.	  The	   longevity	   of	   the	   JE-­‐VC–elicited	   immune	   response	   has	   been	   studied	   in	  different	   non-­‐endemic	   populations116,119,120.	   One	   study	   in	   Austrian,	   German,	   and	  Romanian	  adults	   recorded	  a	  95%	  seroprotection	   rate	  at	   six	  months,	   and	  83%	  at	  12	  months119,	  whereas	  another	  study	  in	  Northern	  Irish	  and	  German	  adults	  showed	  lower	  rates	  of	   long-­‐term	  seroprotection:	  83%	  at	  six	  months,	  58%	  after	  one	  year,	  and	  48%	  after	   two	   years	   following	   primary	   immunization116.	   The	   longer	   duration	   of	  seroprotection	   observed	   in	   the	   first	   study	   might	   be	   due	   to	   a	   priming	   effect	   of	  preceding	  tick-­‐borne	  encephalitis	  (TBE)	  vaccinations121;	  a	  majority	  of	  the	  subjects	  in	  the	  first	  study	  had	  previously	  been	  immunized	  against	  TBE,	  compared	  to	  none	  with	  a	  history	   of	   TBE	   vaccinations	   in	   the	   second	   study116.	   A	   third	   study	   in	   Austrian	   and	  German	  adults	  with	  no	  reports	  on	  preceding	   flavivirus	  vaccinations	  recorded	  a	  69%	  seroprotection	  rate	  15	  months	  after	  the	  primary	  series120.	  According	  to	  manufacturer’s	  guidelines,	  the	  first	  JE-­‐VC	  booster	  dose	  should	  be	  given	  12	  to	  24	  months	  after	  the	  primary	  series,	  whereas	  no	  recommendations	  exist	  on	  the	  need	  of	  subsequent	  boosters115.	  A	  booster	  dose	  given	  at	  11,	  15,	  or	  23	  months	  has	  proven	  immunogenic116,120.	  The	  majority	  of	  those	  who	  received	  a	  booster	  at	  11	  or	  15	  months	  were	   still	   protected	  one	   year	   later116,120.	  According	   to	  model	   predictions	  on	  antibody	   kinetics,	   a	   majority	   of	   vaccinees	   will	   maintain	   protective	   titers	   of	  neutralizing	  antibodies	  against	  the	  vaccine	  strain	  for	  at	  least	  four	  years	  after	  the	  first	  booster	  dose120.	  
Safety	  
The	   safety	  profile	   of	   JE-­‐VC	  was	   evaluated	   in	   a	   pooled	   analysis	  with	  data	   from	  4043	  adult	   vaccinees122.	   Local	   AE:s	  were	   reported	   by	   54%	  of	   subjects,	   the	  most	   common	  local	  symptoms	  being	  pain	  (33%)	  and	  tenderness	  (33%),	   followed	  by	  redness	  (9%),	  hardening	   (8%),	   swelling	   (5%),	   and	   itching	   (4%).	   Approximately	   40%	   of	   vaccine	  recipients	   experienced	   at	   least	   one	   systemic	   AE	   related	   to	   vaccination,	   the	   most	  common	  side	  effects	  being	  headache	  (19%),	  myalgia	  (13%),	  fatigue	  (10%),	  influenza-­‐like	   illness	   (9%),	   and	   nausea	   (5%).	   Two	   percent	   of	   vaccinees	   in	   the	   pooled	   safety	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population	   experienced	   at	   least	   one	   serious	   AE;	   however,	   none	   of	   these	   were	  considered	   vaccine	   related.	   Safety	   of	   JE-­‐VC	   has	   not	   been	   studied	   in	   pregnant,	  breastfeeding,	  or	  immunosuppressed	  persons.	  As	   for	   post-­‐marketing	   surveillance	   data,	   four	   serious	   AE:s	   were	   passively	  reported	  during	  the	  first	  year	  after	  licensure,	  corresponding	  to	  a	  reporting	  rate	  of	  1.6	  serious	  AE:s	  per	  100,000	  doses	  distributed122.	  The	  four	  serious	  AE:s	  included	  neuritis,	  meningism,	  oropharyngeal	  spasm,	  and	  iritis.	  	  
1.2.12.3	  Live	  attenuated	  SA14-­14-­2	  vaccine	  




1.2.12.4	  Chimeric,	  live	  attenuated	  vaccine	  




1.2.13	  Cross-­protection	  within	  the	  Japanese	  encephalitis	  virus	  group	  
1.2.13.1	  Cross-­protection	  between	  Japanese	  encephalitis	  virus	  genotypes	  	  
All	   the	   JE	   vaccines	   currently	   in	   use	   are	   based	   on	   JEV	   strains	   belonging	   to	   a	   single	  genotype	  (GIII)	  which	  used	  to	  be	  the	  dominant	  genotype	  circulating	  for	  decades.	  The	  recent	  emergence	  of	  GI	  strains	  has	  raised	  a	  concern	  on	  the	  ability	  of	  the	  JE	  vaccines	  to	  confer	  cross-­‐protection	  against	  heterologous	  JEV	  genotypes.	  The	   vaccine-­‐elicited	   cross-­‐protection	   against	   other	   JEV	   genotypes	  has	  mainly	  been	   addressed	   by	   mouse	   studies.	   In	   these	   studies,	   active	   immunization	   with	   GIII	  vaccines	   or	   passive	   transfer	   of	   GIII	   vaccine	   antisera	   has	   usually	   provided	   at	   least	  partial	   protection	   against	   a	   subsequent	   challenge	   with	   heterologous	   JEV	  genotypes91,136.	   In	  one	  study,	  high-­‐titer	  sera	   from	  human	  JE-­‐VC	  and	   JE-­‐MB	  vaccinees	  gave	  complete	  protection	  against	  peripheral	  challenge	  with	  GI,	  while	  lower-­‐titer	  sera	  protected	   only	   0%-­‐44%	   of	   subjects91.	   In	   another	  mouse	   study,	   both	   the	   attenuated	  SA14-­‐14-­‐2	   and	   an	   inactivated	   P3-­‐strain	   vaccine	   provided	   protection	   against	  peripheral	   GI	   challenge,	   but	   when	   exposed	   via	   the	   intracerebral	   route,	   only	   the	  attenuated	  vaccine	  gave	  acceptable	  protection	  against	  GI136.	   In	   a	   third	  mouse	   study,	  hyperimmune	  ascitic	   fluid	   raised	  against	   JE-­‐MB	  or	   JE-­‐CV	  provided	  variable	   levels	   of	  protection	  against	  a	  stringent	  challenge	  with	  GII-­‐GIV	  strains,	  and	  only	  weak	  protection	  against	  GI	  challenge137.	  	  Some	  studies	  in	  humans	  have	  evaluated	  the	  capacity	  of	  the	  GIII	  vaccine–elicited	  antibodies	   to	   neutralize	   test	   strains	   of	   heterologous	   JEV	   genotypes.	   In	   two	   studies	  with	  Thai	  children	  and	  Australian	  adults,	  70%-­‐97%	  of	  vaccinees	  developed	  protective	  levels	  of	  GI-­‐GIV	  neutralizing	  antibodies	  after	  primary	  immunization	  with	  JE-­‐CV133,138.	  One	  Taiwanese	   study	   explored	   the	   long-­‐term	   seroprotection	   in	   children	   immunized	  with	  JE-­‐MB	  (three-­‐dose	  primary	  immunization	  at	  1.5-­‐2.5	  years	  of	  age	  and	  booster	  at	  around	  7-­‐8	  years	  of	  age).	   In	   that	  study,	   less	   than	  50%	  of	  5-­‐15	  year-­‐old	  children	  had	  neutralizing	   antibodies	   against	   the	   GI	   test	   strain,	   while	   a	   significantly	   higher	  percentage	  were	  seroprotected	  against	  the	  vaccine	  strain	  Nakayama139.	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1.2.13.2	   Cross-­protection	   between	   different	   species	   of	   Japanese	   encephalitis	  
virus	  group	  
















The	  four	  antigenically	  distinct	  serotypes	  of	  dengue	  virus	  (DENV)	  comprise	  the	  dengue	  virus	  group	  in	  genus	  Flavivirus,	  family	  Flaviviridae.	  Infection	  with	  any	  of	  the	  serotypes	  (DENV-­‐1	  to	  DENV-­‐4)	  can	  cause	  a	  wide	  spectrum	  of	  clinical	  disease	  in	  humans,	  ranging	  in	   severity	   from	   a	   mild	   undifferentiated	   fever	   to	   a	   severe	   life-­‐threating	   systemic	  illness.	  
1.3.2	  Transmission	  
DENV	  is	  transmitted	  between	  humans	  by	  Aedes	  mosquitoes.	  The	  urban-­‐adapted	  Aedes	  
aegypti	  is	  the	  most	  important	  vector153.	  It	  feeds	  primarily	  on	  humans	  during	  the	  day-­‐time,	   both	   indoors	   and	   outdoors,	   and	   is	   capable	   of	   biting	   several	   people	   in	   a	   short	  period	   of	   time.	   The	   mosquito	   oviposits	   in	   diverse	   natural	   and	   artificial	   water	  containers.	  The	  viruses	   can	  also	  be	   transmitted	  by	  other	   species	  of	   the	  genus	  Aedes	  mosquitoes,	  including	  Aedes	  albopictus,	  Aedes	  polynesiensis,	  and	  members	  of	  the	  Aedes	  


















Figure	   4.	   The	   distribution	   and	   burden	   of	   dengue	   in	   2010.	   Evidence	   consensus	   on	   presence	   of	  
dengue	  (a),	  probability	  of	  dengue	  occurrence	  (b),	  and	  annual	  number	  of	  infections	  (c)	  in	  different	  





1.3.4	  Clinical	  features	  
1.3.4.1	  The	  clinical	  course	  
DENV	  has	  an	  incubation	  period	  of	  3	  to	  10	  days.	  Infection	  can	  be	  subclinical,	  or	  cause	  a	  variety	   of	   clinical	  manifestations	   ranging	   in	   severity	   from	  a	  benign	   febrile	   illness	   to	  life-­‐threatening	  complications171.	  Characteristically,	   the	   illness	   course	   follows	   three	   phases:	   the	   febrile,	   the	  critical,	  and	  the	  recovery	  phase.	  The	  initial	  febrile	  phase	  starts	  with	  an	  abrupt	  onset	  of	  high-­‐grade	   fever.	  Other	   typical	   symptoms	   include	  severe	  headache	  and	   retro-­‐orbital	  pain,	   nausea	   and	   vomiting,	   flushed	   facies,	   and	   skin	   erythema172,173.	   Patients	   often	  complain	   of	  myalgia,	   arthralgia,	   or	   generalized	   body	   ache.	   Some	   patients	   have	  mild	  respiratory	  symptoms	  or	  conjunctival	  injection.	  The	  febrile	  phase	  usually	  lasts	  2	  to	  7	  days.	   Primary	   infections	   have	   a	   longer-­‐lived	   febrile	   period	   than	   secondary	  infections165,174.	  While	  the	  vast	  majority	  of	  patients	  recover	  spontaneously	  after	  a	  benign	  illness	  course,	   some	   are	   at	   risk	   for	   developing	   a	   severe	   vascular	   leakage	   syndrome	  which	  becomes	  apparent	  around	  the	  time	  of	  defervescence.	  These	  patients	  may	  experience	  an	   increase	   in	   capillary	   permeability,	   as	   evidenced	   by	   a	   rising	   hematocrit,	  hypoproteinemia,	  pleural	  effusions,	  or	  ascites11.	  The	  critical	  phase	  typically	  lasts	  1	  to	  2	  days155.	   The	   degree	   of	   extravasation	   varies;	   if	   a	   critical	   plasma	   volume	   is	   lost,	   the	  patient	   passes	   into	   a	   state	   of	   shock.	   During	   the	   initial	   stage,	   physiological	  compensatory	  mechanisms	  are	  able	  to	  maintain	  a	  normal	  systolic	  blood	  pressure.	  The	  patient	  has	  tachycardia,	  cold	  extremities,	  and	  a	  delayed	  capillary	  refill	  time.	  As	  a	  result	  of	   increased	   vascular	   resistance,	   the	   pulse	   pressure	   narrows.	   Later,	   as	   the	  compensatory	  mechanisms	  become	  insufficient,	  the	  systolic	  blood	  pressure	  decreases	  rapidly.	  A	  profound	  hypotensive	  shock	  has	  a	  difficult	  clinical	  course	  and	  may	  lead	  to	  multiple	   organ	   failure	   and	   advanced	   disseminated	   intravascular	   coagulation.	  Development	  of	  a	  clinically	  significant	  vascular	  leakage	  syndrome	  is	  often	  preceded	  by	  warning	   signs,	   such	   as	   acute	   abdominal	   pain,	   persistent	   vomiting,	   lethargy	   and	  restlessness,	  or	  increase	  in	  hematocrit	  concurrently	  with	  a	  rapid	  decrease	  in	  platelet	  count175.	  	  Rare	  manifestations	  of	  severe	  disease	  include	  hepatitis176,	  myocarditis177,	  and	  neurological	   manifestations178.	   Neurological	   complications	   associated	   with	   DENV	  infection	   include	   encephalopathy,	   DENV	   encephalitis,	   post-­‐infectious	   immune-­‐mediated	  syndromes,	  cerebrovascular	  complications,	  muscle	  dysfunction,	  and	  neuro-­‐ophthalmic	  complications178.	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Hemorrhagic	  symptoms	  are	  characteristic	   for	   the	  critical	  period	  but	  may	  also	  be	  present	   during	   the	   febrile	   phase11.	   Patients	   often	  have	   a	   positive	   tourniquet	   test	  (over	   10-­‐20	   petechiae	   per	   2.5	   cm2	   on	   the	   forearm	   after	   having	   an	   inflated	   blood	  pressure	   cuff	   on	   the	   upper	   arm	   for	   5	   minutes).	   Hemorrhagic	   tendency	   may	   also	  manifest	   as	   bleeding	   at	   the	   venipuncture	   site,	   easy	   bruising,	   gingival	   bleeding,	  epistaxis,	   or	   hematuria.	   Severe	   hemorrhagic	   complications,	   such	   as	   massive	  gastrointestinal	  or	  vaginal	  bleeding,	  are	  most	  common	  in	  patients	  with	  shock155.	  During	   the	   early	   recovery	   phase,	   the	   extravascular	   compartment	   fluid	   is	  gradually	  reabsorbed.	  Hypervolemia	  may	  complicate	  the	  illness	  course	  if	  intravenous	  fluids	   have	   been	   administered	   in	   excess.	   Bradycardia	   and	   changes	   in	   the	  electrocardiogram	   are	   common155.	   Some	   patients	   develop	   a	   macular	   rash	   or	  generalized	   pruritus.	   Especially	   adults	   may	   experience	   prolonged	   fatigue	   and	  depression	  after	  the	  acute	  infection11.	  
1.3.4.2	  Classification	  of	  disease	  severity	  
The	  previous	  WHO	  classification	  system	  grouped	  DENV	   infections	   into	   three	  clinical	  categories:	  (1)	  undifferentiated	  fever,	  (2)	  dengue	  fever,	  and	  (3)	  dengue	  hemorrhagic	  fever	   (DHF)179.	   Cases	  were	   classified	  as	  DHF	   if	   the	  patients	  presented	  with	   fever,	   at	  least	   one	   sign	   indicative	   of	   hemorrhagic	   tendency,	   thrombocytopenia	   (100	  000	  cells/mm3	  or	   less),	   and	  evidence	  of	  plasma	   leakage.	  DHF	  cases	  were	   further	  divided	  into	   four	   severity	   grades	   on	   the	   basis	   of	   the	   hemorrhagic	   manifestations	   and	   the	  hemodynamic	   status	   of	   the	   patient.	   The	  most	   severe	   DHF	   grades	   (III	   and	   IV)	   were	  defined	  as	  dengue	  shock	  syndrome	  (DSS).	  Due	   to	   criticism	   of	   previous	   case	   definitions,	   the	  WHO	   classification	   criteria	  were	  revised	  in	  2009155,180.	  The	  new	  classification	  comprises	  three	  clinical	  categories:	  (1)	   dengue	   without	   warning	   signs,	   (2)	   dengue	   with	   warning	   signs,	   and	   (3)	   severe	  dengue155.	   The	   following	   manifestations	   are	   considered	   warning	   signs:	   abdominal	  pain	   or	   tenderness,	   persistent	   vomiting,	   clinical	   fluid	   accumulation,	   mucosal	   bleed,	  lethargy,	  restlessness,	  liver	  enlargement	  >2cm,	  and	  increase	  in	  hematocrit	  concurrent	  with	  rapid	  decrease	   in	  platelet	  count.	  A	  severe	  disease	   is	  defined	  by	  the	  presence	  of	  severe	  plasma	  leakage,	  severe	  bleeding,	  or	  severe	  organ	  involvement.	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1.3.4.3	  Routine	  blood	  laboratory	  findings	  
Leucopenia	  with	  lymphopenia	  is	  usually	  the	  earliest	  abnormality	  detected	  in	  routine	  blood	   laboratory	   tests155.	   Thrombocytopenia	   appears	   later	   than	   leucopenia,	   and	   is	  typically	  observed	  between	  illness	  days	  3	  and	  8.	  	  Hematocrit	   is	   the	   single	   most	   important	   routine	   laboratory	   test	   during	   the	  course	   of	   illness155.	   It	   should	   first	   be	  measured	   early	   in	   the	   illness	   to	   establish	   the	  patient’s	   baseline	   value.	   When	   a	   significant	   plasma	   leakage	   syndrome	   develops,	  hematocrit	   rises,	   typically	   in	   parallel	   with	   a	   rapidly	   decreasing	   platelet	   count.	  Hematocrit	  should	  be	  monitored	  repeatedly	  to	  assess	  the	  stage	  and	  severity	  of	  illness,	  as	  well	   as	   to	   evaluate	   the	   response	   to	  possible	   fluid	   therapy.	   In	   addition	   to	   a	   rising	  value	   associated	   with	   vascular	   leakage,	   a	   decrease	   in	   hematocrit	   should	   alert	   the	  clinician	  as	  this	  may	  indicate	  severe	  hemorrhage.	  Apart	   from	  full	  blood	  cell	  count,	   the	  clinical	  status	  of	   the	  patient	  may	  require	  determination	  of	  other	  laboratory	  values,	  such	  as	  serum	  electrolytes,	  glucose,	  lactate,	  C-­‐reactive	   protein,	   creatinine,	   urea,	   liver	   transaminases,	   and	   cardiac	   biomarkers.	   A	  mild	  elevation	  in	  liver	  transaminases	  is	  a	  common	  finding181.	  
1.3.5	  Microbiological	  diagnostics	  
The	  clinical	  diagnosis	  of	  a	  suspected	  DENV	  infection	  can	  be	  confirmed	  by	  isolation	  of	  the	  virus,	  detection	  of	  viral	  genome	  or	  antigens,	  or	  by	  determination	  of	  virus-­‐specific	  antibodies	  in	  paired	  serum	  samples166.	  The	  choice	  of	  the	  diagnostic	  approach	  depends	  on	  the	  purpose	  of	  testing,	  the	  time	  of	  sample	  collection,	  and	  resources	  available.	  In	   clinical	   settings,	   laboratory	   diagnostics	   of	   dengue	   is	   often	   based	   on	  serological	   tests.	  Enzyme	   immunoassay–based	  methods	  are	  commonly	  used,	  as	   they	  are	  relatively	  easy	  to	  perform,	  inexpensive,	  and	  allow	  differentiation	  between	  primary	  and	   secondary	   infections.	   The	   disadvantages	   of	   serological	   testing	   include	   the	  requirement	  of	  serial	  samples	  for	  confirmed	  diagnosis,	  potential	  cross-­‐reactivity	  with	  other	  flaviviruses,	  and	  possible	  false	  positivity	  in	  some	  other	  conditions182.	  Detection	  of	   virus-­‐specific	   IgM	   antibodies	   or	   a	   high	   titer	   of	   anti-­‐DENV	   IgG	   in	   a	   single	   serum	  sample	   indicates	   probable	   DENV	   infection,	   while	   a	   confirmed	   diagnosis	   requires	  demonstration	   of	   seroconversion	   (IgM	   or	   IgG)	   or	   at	   least	   a	   four-­‐fold	   rise	   in	   IgG	  titer155,166.	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1.3.6	  Treatment	  and	  prognosis	  	  
Currently,	  no	  effective	  antiviral	  therapy	  exists	  for	  dengue.	  Uncomplicated	  cases	  can	  be	  treated	   at	   home	   but	   should	   be	   monitored	   daily	   until	   the	   critical	   period	   is	   over155.	  Symptomatic	  treatment	  of	  these	  patients	  consists	  of	  paracetamol	  and	  adequate	  intake	  of	  oral	  fluids.	  Non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs)	  should	  be	  avoided	  due	  to	  their	  antiplatelet	  properties.	  	  Development	  of	  any	  of	  the	  warning	  signs	  or	  severe	  manifestations	  indicates	  a	  need	   for	   hospitalization.	   During	   the	   phase	   of	   plasma	   leakage,	   restoration	   of	   plasma	  volume	  by	  adequate	   fluid	  resuscitation	   is	  essential.	   Isotonic	  crystalloid	  solutions	  are	  preferred	   for	   treatment	   of	   compensated	   shock;	   in	   hypovolemic	   shock,	   colloid	  solutions	   may	   be	   needed.	   Excessive	   administration	   of	   intravenous	   fluids	   should	   be	  avoided	  due	  to	  the	  risk	  of	  hypervolemia	  which	  is	  a	  common	  complication	  during	  the	  recovery	   phase.	   In	   addition	   to	   administration	   of	   intravenous	   fluids,	   patients	   with	  severe	   manifestations	   may	   require	   adjuvant	   therapy,	   such	   as	   vasopressor	   and	  inotropic	  agents,	  blood	   transfusion,	   renal	   replacement	   therapy,	  or	   further	   treatment	  of	  organ	  impairment.	  Severe	  cases	  should	  be	  treated	  in	  high-­‐dependency	  or	  intensive	  care	  units.	   The	   case-­‐fatality	   rate	  may	  be	   as	  high	   as	  12%	  but	   can	  be	   reduced	   to	   less	  than	  1%	  with	  adequate	  treatment155.	  	  
1.3.7	  Pathogenesis	  
Monocytes,	   macrophages,	   and	   dendritic	   cells	   have	   been	   proposed	   as	   the	   primary	  target	  cells	  of	  DENV	  infection191-­‐193.	  After	  inoculation	  of	  the	  virus	  into	  the	  skin	  through	  the	  bite	  of	  an	  infected	  mosquito,	  keratinocytes	  and	  skin	  dendritic	  cells	  are	  potentially	  the	  first	  cells	  to	  become	  infected191,194.	  It	  is	  believed	  that	  the	  activated	  dendritic	  cells	  then	   migrate	   to	   lymph	   nodes,	   cells	   of	   the	   macrophage-­‐monocyte	   lineage	   become	  infected,	  and	  the	  infection	  is	  disseminated	  to	  other	  sites	  through	  the	  lymphatic	  system	  and	  blood.	  	  The	  pathogenesis	  of	  dengue	  remains	   largely	  unresolved.	  The	  absence	  of	  good	  animal	  models	   has	   hampered	   efforts	   to	   understand	   the	  mechanisms	   underlying	   the	  clinically	   important	  disease	  manifestations.	  According	   to	   current	  understanding,	   the	  pathogenesis	  of	  severe	  dengue	  is	  a	  complex	  interplay	  between	  host	  immune	  response,	  other	  host	  factors,	  and	  virulence	  of	  the	  virus195.	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Several	  studies	  have	  identified	  secondary	  DENV	  infection	  as	  a	  risk	  factor	  for	  a	  complicated	   illness	  course161-­‐165.	   In	  addition,	  primary	   infections	  of	   infants	  have	  been	  associated	  with	   a	   severe	   illness161,196.	   Pre-­‐existing,	   non-­‐neutralizing	   antibodies	   have	  been	  proposed	  to	  explain	  the	  more	  severe	  illness	  seen	  in	  secondary	  infections	  and	  in	  primary	   infections	   of	   infants197,198.	   According	   to	   the	   theory	   of	   antibody-­‐dependent	  enhancement	   (ADE),	   non-­‐neutralizing	   cross-­‐reactive	   antibodies	   bind	   the	   virus	   and	  facilitate	  its	  entry	  into	  Fc	  receptor-­‐bearing	  cells,	  consequently	  increasing	  the	  number	  of	  virus-­‐infected	  cells.	  A	  high	  level	  of	  viremia	  has	  been	  shown	  to	  be	  associated	  with	  a	  severe	  illness199,200.	  Recent	   studies	   have	   suggested	   that	   immature	   virus	   particles	   may	   play	   an	  important	  role	   in	  ADE201,202.	  DENV-­‐infected	  cells	  are	  known	  to	  secrete	  high	   levels	  of	  immature	   virus	   particles	  which	   contain	   precursor	   forms	   of	   the	  M	   protein	   (prM)203.	  Antibodies	   against	   DENV	   prM	   are	   known	   to	   be	   highly	   cross-­‐reactive,	   but	   non-­‐neutralizing	   even	   at	   high	   concentrations202.	   In	   vitro	   studies	   have	  demonstrated	   that	  anti-­‐prM	   antibodies	   are	   able	   to	   mediate	   ADE,	   allowing	   otherwise	   non-­‐	   or	   less-­‐infectious	  immature	  virus	  particles	  to	  enter	  Fc	  receptor–bearing	  cells	  and	  to	  become	  infectious201,202.	  Pathogenic	  memory	  T-­‐cell	  responses,	  increased	  expression	  of	  certain	  pro-­‐inflammatory	  cytokines,	  and	  activation	  of	  the	  complement	  system	  have	  also	  been	  associated	  with	  the	  pathogenesis	  of	  severe	  illness195,204.	  	  The	   levels	  of	  DENV	  NS1	  antigen	   in	  patient	   sera	  have	  been	   found	   to	   correlate	  with	  the	  severity	  of	  illness205.	  The	  glycoprotein	  may	  be	  involved	  in	  the	  pathogenesis	  of	  severe	  infections,	  although	  the	  mechanism	  remains	  unclear.	  NS1	  has	  been	  proposed	  to	  protect	   DENV	   from	   complement-­‐dependent	   neutralization206,207,	   and	   to	   elicit	  autoantibodies	  that	  cross-­‐react	  with	  platelet	  and	  extracellular	  matrix	  antigens208,209.	  
1.3.8	  Control	  
Despite	   active	   research	   in	   the	   field,	   no	   licensed	   vaccine	   is	   as	   yet	   available	   against	  dengue.	  The	  prevention	  of	  human	  cases	   relies	  on	  efforts	   to	   control	  vector	  mosquito	  populations.	  The	  most	  important	  means	  is	  elimination	  and	  management	  of	  containers	  that	  provide	  breeding	  sites	   for	  Aedes	  aegypti175.	  Chemical	   insecticides	  have	  a	   limited	  effect,	   and	   should	   only	   be	   used	   complementary	   to	   a	   more	   comprehensive	  environmental	   management	   approach.	   Biological	   control	   of	   mosquitoes	   by	  larvivorous	   fish	   or	   predatory	   copepods	   has	   proven	   effective	   in	   some	   settings210,211.	  Novel	  vector	  control	  strategies	  are	  actively	  studied.	  One	  such	  approach	  is	  to	  introduce	  a	   DENV	   infection	   inhibiting	   bacterium	   (intracellular	  Wolbachia)	   into	   Aedes	   aegypti	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populations212-­‐214.	   Another	   strategy	   is	   to	   eliminate	   vectors	   by	   releasing	   genetically	  engineered	   variants	   into	   the	   target	   population215.	   Personal	   protective	   measures	   to	  reduce	   human-­‐vector	   contact	   include	   use	   of	   protective	   clothing,	   insect	   repellents,	  insecticide-­‐treated	  mosquito	  nets,	  and	  mosquito	  screening	  on	  windows	  and	  doors.	  	  
1.3.9	  Dengue	  in	  travelers	  
Many	  of	  the	  DENV	  endemic	  areas	  are	  popular	  tourist	  destinations,	  and	  concomitantly	  with	   the	   global	   emergence	   of	   the	   disease,	   reports	   on	   travel-­‐acquired	   cases	   have	  increased172,216.	  In	  specialized	  travel	  and	  tropical-­‐medicine	  clinics,	  dengue	  has	  become	  the	   most	   common	   cause	   of	   a	   systemic	   febrile	   illness	   in	   travelers	   returning	   from	  Southeast	  Asia,	  South	  Central	  Asia,	  South	  America,	  and	  the	  Caribbean217.	  	  The	   risk	   for	   acquiring	   dengue	   during	   travel	   has	   been	   estimated	   by	  mathematical	   models	   and	   prospective	   serological	   studies218-­‐223.	   Serological	   studies	  have	  recorded	  DENV	  infection	  attack	  rates	  of	  0.2%-­‐6.7%	  in	  Swiss,	  Australian,	  Dutch,	  and	   Israeli	   travelers	   to	  endemic	  countries218,220,221,223,224.	   Some	  of	   these	  studies	  may,	  however,	   slightly	   overestimate	   the	   true	   rate	   of	   infections	   because	   of	   possible	   false	  positive	  test	  results	  caused	  by	  cross-­‐reactive	  immune	  responses	  to	  other	  flaviviruses.	  DENV	   infection	   risk	   has	   been	   shown	   to	   vary	   greatly	   based	   on	   the	   season,	  duration,	   and	   destination	   of	   travel217,219,222.	   In	   travelers	   visiting	   Thailand	   for	   one	  week,	  the	  estimated	  risk	  of	  acquiring	  the	  virus	  was	  0.2%	  during	  the	  peak	  transmission	  season,	   and	   only	   0.00008%	  during	   the	   dry	   season222.	   In	   Singapore,	   during	   the	   high	  transmission	   season	   in	  2005,	   the	   infection	   risk	  was	  0.17%	   for	   travelers	   staying	  one	  week,	  and	  4.57%	  for	  those	  staying	  six	  months219.	  	  In	  different	  case	  series,	  Southeast	  Asia	  is	  often	  one	  of	  the	  most	  common	  regions	  to	   acquire	   the	   disease.	   Among	   888	   dengue	   patients	   presenting	   to	   18	   clinics	   of	   the	  global	  GeoSentinel	  network	  in	  2000-­‐2010,	  the	  most	  common	  travel	  destinations	  were	  Southeast	   Asia	   (50%)	   and	   South-­‐Central	   Asia	   (17%)225.	   Similarly,	   among	   219	  European	   travelers	   (2003-­‐2005),	   the	   infection	   was	   most	   commonly	   acquired	   in	  Southeast	  Asia	  (35%),	  or	  in	  the	  Indian	  subcontinent	  (29%)226.	  Of	  the	  Swedish	  patients	  diagnosed	  with	  dengue	  in	  2005-­‐2008,	  over	  75%	  had	  been	  infected	  in	  Southeast	  Asia,	  most	   of	   them	   in	   Thailand227.	   In	   Australian	   traveler	   patients	   from	   years	   1999-­‐2012,	  more	   than	   half	   had	   acquired	   the	   disease	   in	   Indonesia,	  mainly	   in	   Bali228.	   Among	   US	  travelers	   diagnosed	  with	   dengue	   in	   1996-­‐2005,	   the	  most	   commonly	   visited	   regions	  were	   the	   Caribbean,	   Central	   America,	   and	  Mexico	   (around	   60%	   of	   the	   cases	  with	   a	  known	  travel	  history),	  followed	  by	  Southeast	  Asia	  (24%)229.	  As	  evident,	  the	  case	  series	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Figure	  5.	  Number	  of	  travel-­‐acquired	  dengue	  cases	  in	  Finland,	  1985-­‐2012.	  During	  the	  time	  period,	  
the	   laboratory	   diagnostics	   of	   DENV	   infections	   was	   based	   on	   detection	   of	   virus-­‐specific	   IgM	  































Year	  of	  infecYon	  
	  45	  
	  
2. AIMS OF THE STUDY 
The	  main	  aim	  of	  this	  thesis	  was	  to	  find	  solutions	  to	  some	  practical	  clinical	  questions,	  and	   thus	   provide	   clinically	   important	   new	   data	   on	   travel-­‐associated	   flavivirus	  infections.	  	  Studies	   I-­‐III	   addressed	   the	   immunogenicity	   of	   the	   inactivated	   Japanese	   encephalitis	  vaccines,	  JE-­‐VC	  and	  JE-­‐MB,	  in	  Finnish	  and	  Swedish	  adult	  travelers.	  	  Study	   IV	   examined	   the	   diagnostics	   and	   the	   clinical	   picture	   of	   dengue	   in	   Finnish	  traveler	  patients.	  	  The	  specific	  aims	  were	  to:	  	  
• assess	  the	  immunogenicity	  of	  a	  single	  dose	  of	  the	  SA14-­‐14-­‐2–based	  JE-­‐VC	  vaccine	  in	  travelers	  primed	  with	  a	  heterologous	  preparation,	  the	  Nakayama-­‐based	  JE-­‐MB	  vaccine	  (I,	  III)	  
	  
• evaluate	  the	  immune	  responses	  elicited	  by	  the	  two	  inactivated	  JE	  vaccines	  	  	  	  	  (JE-­‐VC,	  JE-­‐MB)	  against	  heterologous	  JEV	  strains	  and	  genotypes	  (II,	  III)	  	  
• examine	  the	  duration	  of	  the	  specific	  and	  the	  cross-­‐protective	  immune	  responses	  after	  primary	  and	  booster	  immunization	  with	  JE-­‐VC	  (III)	  
	  
• study	  the	  kinetics	  of	  viremia	  and	  NS1	  antigenemia	  in	  travel-­‐acquired	  dengue	  (IV)	  
	  









3. MATERIALS AND METHODS 
3.1	  Studies	  I-­III:	  Immunogenicity	  of	  the	  inactivated	  Japanese	  
encephalitis	  vaccines	  in	  Finnish	  and	  Swedish	  adult	  travelers 
3.1.1	  Subjects	  and	  serum	  samples	  




Table	  3.	  Study	  groups.	  
	  	   Group	  MB	  	   Group	  VC	  	   Group	  MB-­‐MB	   Group	  MB-­‐VC	  
Prior	  history	  of	  	  	  	  	  	  	  
JE	  vaccinations	  
none	   none	   primary	  series	  
with	  JE-­‐MB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(JE	  Vaccine	  GCC)	  
primary	  series	  
with	  JE-­‐MB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(JE	  Vaccine	  GCC)	  
JE	  vaccines	  given	  
at	  travel	  clinic	  
primary	  series	  
with	  JE-­‐MB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(JE	  Vaccine	  GCC)	  
primary	  series	  
with	  JE-­‐VC	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(Ixiaro)	  
a	  booster	  of	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
JE-­‐MB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(JE	  Vaccine	  GCC)	  
a	  booster	  of	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




3	  doses	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(day	  0	  +	  7	  +	  30)	  
2 doses	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(day	  0	  +	  28)	  
single	  dose	   single	  dose	  
	  
	  
3.1.2	  Laboratory	  analyses	  





Table	  4.	  JEV	  test	  strains	  used	  in	  studies	  I-­‐III.	  	  
Strain	   Genotype	   Isolation	  year	   Isolation	  place	   Isolation	  source	   Study	  
1991	   GI	   1991	   Korea	   mosquito	   III	  
SM-­‐1	   GI	   2002	   Thailand	   pig	   II,	  III	  
1034/8	   GII	   1983	   Thailand	   mosquito	   II,	  III	  
Nakayama	   GIII	   1935	   Japan	   human	  (fatal	  case)	   I,	  II,	  III	  
Beijing-­‐3	   GIII	   1949	   China	   human	  (fatal	  case)	   III	  
SA14-­‐14-­‐2*	   GIII	   1954	  (SA14)	   China	  (SA14)	   mosquito	  (SA14)	   I,	  II,	  III	  
9092	   GIV	   1981	   Indonesia	   mosquito	   II,	  III	  
*	  SA14-­‐14-­‐2	  is	  an	  attenuated	  strain.	  The	  parental	  strain	  SA14	  was	  isolated	  from	  mosquitoes	  in	  
China	  in	  1954.	  	   	   	   	   	  
	  
3.1.3	  Statistical	  analyses	  
Statistical	  analyses	  were	  performed	  with	  the	  R	  2.13.0	  software231.	  Two-­‐sided	  χ2	  tests	  and	  two-­‐sided	  Wilcoxon	  exact	  tests	  were	  used	  for	  assessing	  the	  statistical	  significance	  of	  observed	  differences.	  P	  values	  <0.05	  were	  considered	  significant.	  
3.1.4	  Research	  clearances	  
The	   study	   (EudraCT:	   2010-­‐023300-­‐27;	   ClinicalTrials.gov:	   NCT01386827)	   was	  approved	  by	  the	  local	  ethics	  committees	  in	  Helsinki	  (Ethics	  Committee,	  Department	  of	  Medicine,	  Hospital	  District	  of	  Helsinki	  and	  Uusimaa)	  and	   in	  Stockholm	  (the	  Regional	  Ethical	  Review	  Board	  in	  Stockholm).	  All	  participants	  provided	  informed	  consent.	  
3.1.5	  Funding	  of	  the	  studies	  
Study	  I	  was	  supported	  in	  part	  by	  Novartis	  Vaccines	  and	  Diagnostics	  (assay	  expenses),	  by	   a	   specific	   Finnish	   governmental	   subsidy	   for	   health	   science	   research,	   and	   by	  Wiipurilaisen	  Osakunnan	  Stipendisäätiö.	   Shailesh	  Dewasthaly	  and	  Katrin	  Dubischar-­‐Kastner	  (Intercell)	  commented	  on	  a	   late-­‐stage	  draft	  of	   the	  original	  article	   I,	  and	  Lisa	  DeTora	   (Novartis	   Vaccines	   and	   Diagnostics)	   provided	   linguistic	   revisions	   for	   the	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3.2	  Study	  IV:	  Viremia	  and	  NS1	  antigenemia	  in	  travelers’	  dengue	  	  
3.2.1	  Subjects	  
In	  Finland,	  the	  laboratory	  diagnostics	  of	  dengue	  infections	  is	  currently	  centralized	  in	  one	  single	   laboratory	   (HUSLAB,	  Helsinki).	   In	   this	   study,	  we	  retrospectively	  analyzed	  data	   on	   all	   the	   patients	   who	   had	   proven	   positive	   for	   anti-­‐DENV	   IgM	   antibodies	   in	  Finland	  in	  1999-­‐2008	  (154	  patients).	  Those	  with	  insufficient	  clinical	  information	  (57	  patients),	   or	   suspicion	   of	   a	   false	   positive	   IgM	   (four	   patients)	   were	   excluded.	  Consequently,	  a	  total	  of	  93	  cases	  were	  included	  in	  the	  study	  population.	  	  
3.2.2	  Laboratory	  analyses	  
From	  the	  93	  study	  patients,	  we	  collected	  all	  available	  serum	  samples	  taken	  within	  the	  first	  21	  days	  after	  illness	  onset	  (a	  total	  of	  139	  samples,	  1-­‐3	  per	  patient).	  Existing	  data	  archives	   of	   the	   diagnostic	   laboratory	   provided	   the	   serological	   test	   results	   obtained	  with	  a	  commercial	  anti-­‐DENV	  IgM	  enzyme	  immunoassay	  (Focus	  Technologies)	  and	  an	  in-­‐house	   IgG	   immunofluorescence	   assay	   (IFA)232.	   The	   RT-­‐PCR233	   and	   NS1	   tests	  (Platelia	   Dengue	  NS1	  Ag	   EIA,	   Bio-­‐Rad)	  were	   run	   separately	   from	   frozen	   aliquots	   of	  sera.	   A	   subgroup	   of	   samples	   had	   been	   tested	   previously	   as	   a	   part	   of	   a	   separate	  study233.	  The	  test	  protocols	  have	  been	  described	  in	  detail	  previously232,233,IV.	  
3.2.3	  Collection	  of	  clinical	  data	  





3.2.4	  Statistical	  analyses	  
The	   kinetics	   of	   diagnostic	   markers	   were	   studied	   with	   generalized	   additive	   mixed	  models234.	  We	  analyzed	  both	  the	  probability	  of	  test	  positivity	  and	  the	  relative	  levels	  of	  serum	  diagnostic	  markers	  as	  a	  function	  of	  time.	  In	  addition	  to	  a	  single	  test	  approach,	  we	  also	  studied	  all	  the	  possible	  combinations	  of	  two	  diagnostic	  tests.	  The	   associations	   between	   diagnostic	   markers	   and	   clinical	   parameters	   were	  examined	  with	  regression	  models.	  The	   following	  potential	  confounding	   factors	  were	  included	   in	   the	   analyses:	   age,	   sex,	   day	   of	   illness,	   presence	   of	   co-­‐infections,	   and	  presence	  of	  chronic	  diseases.	  Patients	  with	  insufficient	  data	  on	  the	  controlled	  factors	  (n=4)	   were	   excluded	   from	   the	   association	   analyses.	   All	   statistical	   analyses	   were	  carried	  out	  with	  the	  R	  software231.	  The	  statistical	  analyses	  are	  presented	   in	  detail	   in	  the	  original	  articleIV.	  
3.2.5	  Research	  clearances	  
The	  study	  protocol	  received	  approval	  from	  the	  research	  boards	  of	  the	  Department	  of	  Internal	  Medicine	  of	  Helsinki	  University	  Central	  Hospital,	  Helsinki	  University	  Hospital	  laboratory	  (HUSLAB),	  and	  the	  Ministry	  of	  Social	  Affairs	  and	  Health.	  
3.2.6	  Funding	  of	  the	  study	  








4. RESULTS 	  
4.1	   Studies	   I-­III:	   Immunogenicity	   of	   the	   inactivated	   Japanese	  
encephalitis	  vaccines	  in	  Finnish	  and	  Swedish	  adult	  travelers	  
4.1.1	  Characteristics	  of	  the	  study	  population	  
A	  total	  of	  120	  adult	  travelers	  participated	  in	  the	  studies	  exploring	  the	  immunogenicity	  of	   JE-­‐VC	   and	   JE-­‐MB.	   The	   background	   characteristics	   of	   the	   study	   population	   are	  presented	  in	  Tables	  5	  and	  6.	  	  The	   study	   population	   consisted	   of	   both	   males	   (40%)	   and	   females	   (60%).	  Median	   age	   was	   31.0	   years	   (range	   18-­‐72	   years).	   The	   majority	   of	   volunteers	   were	  generally	  healthy	  (94%),	  and	  of	  Finnish	  or	  Swedish	  origin	  (97%).	  None	  of	  the	  subjects	  with	  underlying	   chronic	  diseases	  had	  a	   clinically	   significant	   immunosuppression. Of	  those	  with	   a	  history	  of	   JE-­‐MB	  primary	   immunization,	   39%	  had	   received	   a	   two-­‐dose	  series	  and	  61%	  a	  three-­‐dose	  regimen.	  The	  median	  time	  from	  the	  latest	  JE-­‐MB	  primary	  dose	   to	   the	   booster	   was	   5.0	   years	   (range	   1-­‐20.5	   years).	   Sixty-­‐three	   percent	   of	   the	  travelers	   received	   other	   vaccines,	   or	   a	   prescription	   for	   them,	   at	   the	   same	   visit.	   The	  most	   common	   concomitant	   vaccination	   was	   that	   against	   typhoid	   fever	   (48%	   of	  travelers).	  	   	  
Table	  5.	  Background	  characteristics	  of	  the	  volunteers	  in	  the	  primary	  vaccination	  groups.	  
	  	   Group	  VC	   Group	  MB	  
	  	   I	  (n=31)	   II	  (n=29)	   III	  (n=15)	   I	  (n=15)	   II	  (n=12)	  
	  Age,	  years	  (median,	  range)	   26	   	  (18-­‐69)	   26	   (18-­‐61)	   30	   (21-­‐71)	   32	   (18-­‐49)	   33	   (18-­‐38)	  
	  Sex	   	   	   	   	   	   	   	   	   	   	  
	  	  	  	  	  Male	   39	  %	   (12/31)	   41	  %	   (12/29)	   33	  %	   (5/15)	   60	  %	   (9/15)	   58	  %	   (7/12)	  
	  	  	  	  	  Female	   61	  %	   (19/31)	   59	  %	   (17/29)	   67	  %	   (10/15)	   40	  %	   (6/15)	   42	  %	   (5/12)	  
	  Ethnic	  origin	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
















	  	  	  	  	  Other	   0	  %	   (0/31)	   0	  %	   (0/29)	   0	  %	   (0/15)	   0	  %	   (0/13)	   0	  %	   (0/10)	  
	  Chronic	  diseases	   3	  %	   (1/31)	   3	  %	   (1/29)	   7	  %	   (1/15)	   0	  %	   (0/15)	   0	  %	   (0/12)	  
	  History	  of	  YF	  vaccination	   32	  %	   (10/31)	   31	  %	   (9/29)	   33	  %	   (5/15)	   13	  %	   (2/15)	   17	  %	   (2/12)	  
	  History	  of	  TBE	  vaccination	   19	  %	   (6/31)	   14	  %	   (4/29)	   20	  %	   (3/15)	   27	  %	   (4/15)	   25	  %	   (3/12)	  
	  53	  
	  
Table	  6.	  Background	  characteristics	  of	  the	  volunteers	  in	  the	  booster	  vaccination	  groups.	  
	  	   Group	  MB-­‐VC	   Group	  MB-­‐MB	  
	   I	  (n=42)	   III	  (n=19)	   I	  (n=32)	   III	  (n=14)	  
	  Age,	  years	  (median,	  range)	   32	   (19-­‐63)	   41	   (21-­‐67)	   33	   (19-­‐72)	   36	   (22-­‐65)	  
	  Sex	   	   	   	   	   	   	   	   	  
	  	  	  	  	  Male	   33	  %	   (14/42)	   37	  %	   (7/19)	   41	  %	   (13/32)	   43	  %	   (6/14)	  
	  	  	  	  	  Female	   67	  %	   (28/42)	   63	  %	   (12/19)	   59	  %	   (19/32)	   57	  %	   (8/14)	  
	  Ethnic	  origin	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	  	  	  	  Finnish/Swedish	   98	  %	   (41/42)	   95	  %	   (18/19)	   94	  %	   (29/31)	   93	  %	   (13/14)	  
	  	  	  	  	  Other	   2	  %	   (1/42)	   5	  %	   (1/19)	   6	  %	   (2/31)	   7	  %	   (1/14)	  
	  Chronic	  diseases	   12	  %	   (5/42)	   16	  %	   (3/19)	   3	  %	   (1/32)	   7	  %	   (1/14)	  
	  History	  of	  YF	  vaccination	   33	  %	   (14/42)	   53	  %	   (10/19)	   28	  %	   (9/32)	   29	  %	   (4/14)	  
	  History	  of	  TBE	  vaccination	   21	  %	   (9/42)	   32	  %	   (6/19)	   0	  %	   (0/32)	   0	  %	   (0/14)	  
	  
	  
4.1.2	  Immunogenicity	  of	  primary	  vaccination	  
Seroprotection	  against	  the	  vaccine	  strains	  (Study	  I)	  




Figure	  6.	  Titers	  of	  neutralizing	  antibodies	  after	  primary	  immunization.	  Individual	  PRNT50	  titers	  and	  
their	  geometric	  means	  4-­‐8	  weeks	  after	  receiving	  the	  primary	  series	  with	  JE-­‐VC	  (group	  VC;	  n=31)	  or	  
JE-­‐MB	  (group	  MB;	  n=15).	  The	  grey	  horizontal	  line	  indicates	  the	  threshold	  for	  protection,	  a	  PRNT50	  
titer	  of	  10.	  	  
Seroprotection	  against	  strains	  of	  non-­vaccine	  genotypes	  (Study	  II)	  





Figure	   7.	   Titers	   of	   neutralizing	   antibodies	   against	   heterologous	   JEV	   genotypes.	   The	   individual	  
PRNT50	  titers	  against	  each	  target	  strain	  4-­‐8	  weeks	  after	  a	  primary	  vaccination	  series	  with	  a	  SA14-­‐
14-­‐2–based	  (group	  VC;	  n=29)	  or	  a	  Nakayama-­‐based	  (group	  MB;	  n=12)	  vaccine.	  The	  titer	  values	  of	  
each	  individual	  are	  connected	  by	  a	  thin	  black	  line.	  The	  grey	  horizontal	  lines	  indicate	  the	  threshold	  
for	   protection,	   a	   PRNT50	   titer	   of	   10.	   Following	   test	   strains	   were	   used:	   SM-­‐1	   (GI),	   1034/8	   (GII),	  
Nakayama	  (GIII	  Nak),	  SA14-­‐14-­‐2	  (GIII	  SA),	  and	  9092	  (GIV)	  [Table	  4].	  
	  
	  
Table	   7.	   Short-­‐term	   seroprotection	   after	   primary	   immunization.	   Seroprotection	   rates	   (SPR)	   and	  
geometric	  mean	   titers	   (GMT)	   against	   various	   test	   strains	   4-­‐8	  weeks	   after	   primary	   immunization	  
with	  JE-­‐VC	  (group	  VC;	  n=29)	  or	  JE-­‐MB	  (group	  MB;	  n=12).	  The	  volunteers	  with	  pre-­‐vaccination	  anti-­‐
JEV	  antibodies	  were	  excluded	  from	  the	  analyses.	  
	  	   	  	  	  	  	  	  	  	  	  Group	  VC	   	  	  	  	  	  	  	  	  Group	  MB	  
	  test	  strain	   SPR	   GMT	   SPR	   GMT	  
SM-­‐1	  (GI)	   97	  %	   (28/29)	   55	   92	  %	   (11/12)	   50	  
1034/8	  (GII)	   97	  %	   (28/29)	   811	   92	  %	   (11/12)	   580	  
SA14-­‐14-­‐2	  (GIII)	   97	  %	   (28/29)	   559	   83	  %	   (10/12)	   37	  
Nakayama	  (GIII)	   93	  %	   (27/29)	   118	   100	  %	   (12/12)	   293	  









Follow-­up	  data	  (Study	  III)	  
In	   order	   to	   evaluate	   the	   duration	   of	   protection	   provided	   by	   JE-­‐VC,	   follow-­‐up	   serum	  samples	   were	   collected	   from	   study	   participants	   2.1	   (SD	   0.1)	   years	   after	   primary	  vaccination.	  In	  addition	  to	  using	  a	  test	  strain	  homologous	  to	  the	  vaccine	  strain	  (SA14-­‐14-­‐2),	   the	   neutralizing	   antibodies	   were	   also	   determined	   against	   six	   heterologous	  target	   strains	   to	   assess	   the	   cross-­‐neutralization	   capacity	   of	   the	   sera	   [Table	   4].	   Only	  subjects	   with	   no	   seroprotection	   before	   primary	   vaccination	   were	   included	   in	   the	  analyses.	   Table	   8	   provides	   the	   two-­‐year	   seroprotection	   rates	   and	   geometric	   mean	  titers.	   Of	   the	   subjects	   available	   for	   the	   two-­‐year	   follow-­‐up,	   93%	   (14/15)	   showed	  protective	   levels	   of	   neutralizing	   antibodies	   against	   the	   vaccine	   strain,	   SA14-­‐14-­‐2.	  Eighty-­‐seven	   percent	   (13/15)	   of	   the	   subjects	   had	   protective	   levels	   of	   neutralizing	  antibodies	   against	   the	   two	   other	   GIII	   test	   strains,	   Beijing-­‐3	   and	   Nakayama.	   The	  seroprotection	   rates	   against	   strains	   of	   heterologous	   JEV	   genotypes	   were	   73%	   (GI),	  93%	  (GII),	  and	  87%	  (GIV).	  	  
Table	   8.	   Long-­‐term	   seroprotection	   after	   primary	   immunization	  with	   JE-­‐VC.	   Seroprotection	   rates	  
(SPR)	  and	  geometric	  mean	  titers	  (GMT)	  against	  various	  test	  strains	  2.1	  (SD	  0.1)	  years	  after	  primary	  
immunization	   with	   JE-­‐VC	   	   (n=15).	   The	   volunteers	   with	   pre-­‐vaccination	   anti-­‐JEV	   antibodies	   were	  
excluded	  from	  the	  analyses.	  
	  test	  strain	   SPR	   GMT	  
SM-­‐1	  (GI)	   73	  %	   (11/15)	   52	  
1991	  (GI)	   73	  %	   (11/15)	   61	  
1034/8	  (GII)	   93	  %	   (14/15)	   62	  
SA14-­‐14-­‐2	  (GIII)	   93	  %	   (14/15)	   26	  
Nakayama	  (GIII)	   87	  %	   (13/15)	   24	  
Beijing-­‐3	  (GIII)	   87	  %	   (13/15)	   30	  








4.1.3	  Immunogenicity	  of	  homologous	  and	  heterologous	  booster	  vaccines	  
Booster	  capacity	  of	  homologous	  and	  heterologous	  vaccines	  (Study	  I)	  
Study	  I	  addressed	  the	  booster	  capacity	  of	  the	  SA14-­‐14-­‐2–based	  JE-­‐VC	  and	  Nakayama-­‐based	  JE-­‐MB	  vaccines	  in	  subjects	  primed	  with	  JE-­‐MB.	  Tables	  9	  and	  10	  summarize	  the	  seroprotection	   rates	   and	   geometric	   mean	   titers	   in	   both	   groups	   before	   and	   after	  booster	  vaccination.	  Figure	  8	  shows	  the	  individual	  PRNT50	  titers	  in	  both	  groups	  four	  to	  eight	  weeks	  after	  receiving	  the	  booster	  vaccine.	  	  Among	   travelers	   primed	  with	   JE-­‐MB,	   a	   homologous	   booster	   dose	   resulted	   in	  seroconversion	   or	   at	   least	   a	   two-­‐fold	   increase	   in	   titers	   of	   neutralizing	   antibodies	   in	  91%	   (29/32)	   of	   subjects.	   When	   examining	   only	   those	   unprotected	   at	   baseline,	   the	  response	  rate	  to	  the	  homologous	  booster	  was	  100%	  (9/9).	  The	  response	  rates	  for	  the	  homologous	  booster	  were	  comparable	  with	  those	  seen	  after	  the	  heterologous	  booster:	  95%	   (40/42)	   to	   98%	   (41/42)	   of	   JE-­‐MB–primed	   travelers	   responded	   to	   the	  heterologous	   JE-­‐VC	   booster	   with	   seroconversion	   or	   at	   least	   a	   two-­‐fold	   increase	   in	  titers	   of	   neutralizing	   antibodies.	   A	   subgroup	   analysis	   including	   only	   those	   with	   no	  protection	   at	   baseline	   revealed	   that	   100%	   (17/17)	   of	   JE-­‐MB–primed	   subjects	  seroconverted	   after	   a	   single	   dose	   of	   JE-­‐VC,	   while	   the	   corresponding	   rate	   in	   non-­‐primed	  subjects	  was	  only	  40%	  (10/25)	  (p<.001).	  	  
	  
Table	  9.	  Seroprotection	  rates	  before	  and	  after	  booster	   immunization.	  Seroprotection	  rates	   in	  JE-­‐
MB–primed	   subjects	   before	  booster	   immunization	   (day	  0),	   four	   to	   eight	  weeks	   after	   receiving	   a	  
single	  dose	  of	  a	  homologous	  (JE-­‐MB)	  or	  a	  heterologous	  (JE-­‐VC)	  booster	  vaccine,	  and	  approximately	  
two	  years	  later.	  	  
	  	   day	  0	   4-­‐8	  wks	   2	  yr	  
group	  MB-­‐VC	   	  	   	  	   	  	   	  	   	  	   	  	  
test	  strain	  SA14-­‐14-­‐2	   48	  %	   (20/42)	   98	  %	   (41/42)	   100	  %	   (18/18)	  
test	  strain	  Nakayama	   60	  %	   (25/42)	   100	  %	   (42/42)	   100	  %	   (18/18)	  
group	  MB-­‐MB	   	   	   	   	   	   	  	  
test	  strain	  SA14-­‐14-­‐2	   53	  %	   (17/32)	   97	  %	   (31/32)	   93	  %	   (13/14)	  




Figure	   8.	  Titers	   of	   neutralizing	   antibodies	   after	   booster	   vaccination.	   Individual	   PRNT50	   titers	   and	  
their	   geometric	   means	   in	   JE-­‐MB–primed	   subjects	   four	   to	   eight	   weeks	   after	   receiving	   a	   single	  
booster	  dose	  with	  JE-­‐VC	  (group	  MB-­‐VC;	  n=42)	  or	  JE-­‐MB	  (group	  MB-­‐MB;	  n=32).	  The	  grey	  horizontal	  
line	  indicates	  the	  threshold	  for	  protection,	  a	  PRNT50	  titer	  of	  10.	  	  
	  
Table	  10.	  Geometric	  mean	  titers	  before	  and	  after	  booster	  immunization.	  Geometric	  mean	  titers	  in	  
JE-­‐MB–primed	  subjects	  before	  booster	  immunization	  (day	  0),	  four	  to	  eight	  weeks	  after	  receiving	  a	  
single	  dose	  of	  a	  homologous	  (JE-­‐MB)	  or	  a	  heterologous	  (JE-­‐VC)	  booster	  vaccine,	  and	  approximately	  
two	  years	  later.	  	  
	  	   day	  0	   4-­‐8	  wks	   2	  yr	  
group	  MB-­‐VC	   	  	   	  	   	  	  
test	  strain	  SA14-­‐14-­‐2	   19	   504	   101	  
test	  strain	  Nakayama	   23	   523	   103	  
group	  MB-­‐MB	   	   	   	  
test	  strain	  SA14-­‐14-­‐2	   19	   398	   97	  






Follow-­up	  data	  (Study	  III)	  
In	   order	   to	   study	   the	   longevity	   of	   the	   antibody	   response,	   follow-­‐up	   serum	   samples	  were	   collected	   around	   two	   years	   after	   booster	   vaccination.	   Group	  MB-­‐MB	  provided	  serum	  samples	  2.2	  (SD	  0.3)	  years	  and	  group	  MB-­‐VC	  2.1	  (SD	  0.3)	  years	  after	  receiving	  the	  booster	  dose.	  The	  neutralizing	  antibodies	  were	  determined	  against	  seven	  different	  test	  strains	  (Table	  4).	  Tables	  9	  and	  10	  summarize	  the	  follow-­‐up	  seroprotection	  rates	  and	  geometric	  mean	  titers	  against	  the	  test	  strains	  homologous	  to	  the	  vaccines,	  while	  Table	  11	  presents	  the	  corresponding	  data	  against	  non-­‐vaccine	  test	  strains.	  	  Of	  those	  primed	  and	  boosted	  with	  JE-­‐MB,	  93%	  (13/14)	  had	  protective	  levels	  of	  neutralizing	  antibodies	  against	  the	  vaccine	  strain	  (Nakayama)	  and	  the	  two	  other	  GIII	  test	   strains	   (Beijing-­‐3,	   SA14-­‐14-­‐2)	   at	   the	   two-­‐year	   follow-­‐up.	   The	   corresponding	  seroprotection	  rates	  against	  the	  test	  strains	  of	  heterologous	  genotypes	  were	  93%	  (GI),	  100%	   (GII),	   and	   100%	   (GIV).	   Of	   those	   primed	  with	   JE-­‐MB	   and	   boosted	  with	   JE-­‐VC,	  100%	   (18/18)	   had	   protective	   levels	   of	   neutralizing	   antibodies	   against	   the	   vaccine	  strains	  (Nakayama,	  SA14-­‐14-­‐2)	  and	  a	  heterologous	  GIII	  strain	  (Beijing-­‐3)	  at	  follow-­‐up.	  The	  two-­‐year	  seroprotection	  rates	  against	   test	  strains	  of	  other	  genotypes	  were	  89%	  (GI),	  95%	  (GII),	  and	  95%	  (GIV).	  	  	  
Table	   11.	   Seroprotection	   against	   non-­‐vaccine	   JEV	   strains	   and	   genotypes.	   Seroprotection	   rates	  
(SPR)	  and	  geometric	  mean	  titers	   (GMT)	   in	   JE-­‐MB–primed	  subjects	  approximately	   two	  years	  after	  
receiving	  a	  heterologous	  (group	  MB-­‐VC)	  or	  a	  homologous	  (group	  MB-­‐MB)	  booster	  vaccine.	  
	  	   	  	  	  	  	  	  	  	  	  	  	  	  Group	  MB-­‐VC	   	  	  	  	  	  	  	  	  Group	  MB-­‐MB	  
test	  strain	  	   SPR	   GMT	   SPR	   GMT	  
SM-­‐1	  (GI)	   89	  %	   (16/18)	   118	   93	  %	   (13/14)	   573	  
1991	  (GI)	   89	  %	   (17/19)	   142	   93	  %	   (13/14)	   582	  
1034/8	  (GII)	   95	  %	   (18/19)	   217	   100	  %	   (14/14)	   361	  
Beijing-­‐3	  (GIII)	   100	  %	   (19/19)	   122	   93	  %	   (13/14)	   109	  







4.2	  Study	  IV:	  Viremia	  and	  NS1	  antigenemia	  in	  travelers’	  dengue	  
4.2.1	  Clinical	  data	  








Table	  12.	  Laboratory	  findings	  in	  study	  patients*.	  
Finding	   %	   n	  
Anaemia	  (<134/117	  g/L)	   9	  %	   (5/56)	  
Elevated	  hemoglobin	  (>167/155	  g/L)	   13	  %	   (11/87)	  
Low	  hematocrit	  (<39%/35%)	   9	  %	   (5/56)	  
Elevated	  hematocrit	  (>50%/46%)	   8	  %	   (7/87)	  
Leukopenia	  (<3.4	  x109/L)	   67	  %	   (59/88)	  
Thrombocytopenia	  (<150	  x109/L)	   78	  %	   (68/87)	  
Elevated	  AST	  (>45/35	  U/L)	   78	  %	   (49/63)	  
Elevated	  ALT	  (>70/45	  U/L)	   61	  %	   (51/83)	  
Elevated	  creatinine	  (>100/90	  µmol/L)	   25	  %	   (10/40)	  
*	  Reference	  values	  for	  males	  and	  females	  in	  parentheses	  
	  
4.2.2	  Associations	  between	  virologic	  markers	  and	  clinical	  parameters	  




4.2.3	  Kinetics	  of	  the	  diagnostic	  markers	  














5.1	  Studies	  I-­III:	  Immunogenicity	  of	  the	  inactivated	  Japanese	  
encephalitis	  vaccines	  in	  Finnish	  and	  Swedish	  adult	  travelers	  
5.1.1	  Primary	  immunization:	  seroprotection	  against	  vaccine	  strains	  
The	   first	   three	   studies	   (I-­‐III)	   evaluated	   the	   immunogenicity	   of	   the	   inactivated	   JE	  vaccines,	  JE-­‐VC	  and	  JE-­‐MB,	  in	  Finnish	  and	  Swedish	  travelers.	  In	  study	  I,	  both	  JE-­‐VC	  and	  JE-­‐MB	   were	   shown	   to	   be	   highly	   immunogenic	   in	   Northern	   European	   travelers:	   a	  primary	   immunization	   with	   either	   preparation	   induced	   neutralizing	   antibodies	  against	  the	  vaccine	  strains	  in	  the	  vast	  majority	  (87%-­‐100%)	  of	  study	  participants.	  The	  seroprotection	  rates	  recorded	  were	  in	  line	  with	  results	  from	  previous	  immunogenicity	  studies	  in	  non-­‐endemic	  populations.	  In	  a	  large	  non-­‐inferiority,	  randomized	  controlled	  trial,	   98%	   of	   European	   and	   Northern	   American	   adults	   seroconverted	   after	   JE-­‐VC	  primary	   series,	   and	   95%	   after	   JE-­‐MB	   primary	   immunization103.	   An	   earlier	   study	   in	  British	  and	  Nepalese	  adults	  demonstrated	  a	  seroconversion	  rate	  of	  89%	  for	  the	  three-­‐dose	  primary	  series	  with	  JE-­‐MB98.	  Many	  previous	  JE	  vaccine	  studies,	  including	  immunogenicity	  trials	  with	  JE-­‐VC,	  have	  evaluated	  the	  vaccine-­‐induced	  neutralizing	  antibodies	  using	  only	  one	  test	  strain	  which	  has	  usually	  been	  homologous	   to	   the	  vaccine	   strain99,102,116,120.	  This	   single	   test	  strain–approach	   has	   even	   been	   used	   when	   comparing	   the	   immunogenicity	   of	   two	  heterologous	   vaccines103,119.	   In	   study	   I,	   the	   JE-­‐VC	   and	   JE-­‐MB–elicited	   neutralizing	  antibodies	  were	  determined	  using	  both	  vaccine	  strains,	  SA14-­‐14-­‐2	  and	  Nakayama,	  as	  test	   strains.	   This	   approach	   revealed	  notable	   differences	   in	   the	   levels	   of	   neutralizing	  antibodies;	  the	  titers	  were	  significantly	  higher	  against	  the	  vaccine	  strain	  than	  against	  the	  heterologous	   test	   strain.	  Higher	  antibody	   responses	   to	  homologous	   strains	  have	  also	  been	  reported	  previously133,235.	  This	  observation	  is	  of	  importance,	  since	  it	  implies	  that	   a	   PRNT	   target	   strain	  homologous	   to	   one	  but	   heterologous	   to	   the	   other	   vaccine	  strain	  may	  introduce	  a	  bias	  in	  favor	  of	  the	  homologous	  vaccine.	  Our	  data	  thus	  indicate	  that	  comparative	  vaccine	  studies	  using	  vaccine	  strains	  as	  PRNT	  target	  strains	  should	  include	   analyses	   against	   both	   strains	   to	   avoid	   a	   test	   strain-­‐dependent	   bias	   favoring	  either	  vaccine.	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Study	  III	  addressed	  the	  duration	  of	  seroprotection	  after	   JE-­‐VC	  primary	  series.	  At	   the	   two-­‐year	   follow-­‐up,	   the	   majority	   (93%)	   of	   JE-­‐VC	   primed	   subjects	   were	   still	  seroprotected	  against	  the	  vaccine	  strain	  SA14-­‐14-­‐2.	  The	  seroprotection	  rate	  recorded	  in	   study	   III	  was	   higher	   than	   reported	   previously116,119,120.	   A	   study	   in	  Northern	   Irish	  and	  German	  adults	  has	  reported	  the	  lowest	  rates	  of	  long-­‐term	  seroprotection:	  58%	  at	  one	  year,	  and	  48%	  at	  two	  years	  after	  JE-­‐VC	  primary	  immunization116.	  Another	  study	  in	  Austrian,	   German,	   and	   Romanian	   adults	   reported	   a	   one-­‐year	   seroprotection	   rate	   of	  83%119,	  while	  a	  third	  one	  in	  Austrian	  and	  German	  adults	  reported	  a	  rate	  of	  69%	  at	  15	  months	  after	  the	  primary	  series120.	  One	  possible	   explanation	   for	   the	   long	  duration	   of	   protection	   observed	   in	   the	  present	   study	   might	   be	   the	   TBE	   and	   YF	   vaccination	   history	   in	   some	   of	   the	   study	  participants.	  Differences	   in	  TBE	  vaccination	  status	  have	  been	  suggested	  to	  affect	   the	  duration	  of	   immunity	   after	   JE-­‐VC	  primary	   series116.	   In	   addition,	   as	  many	  volunteers	  visited	  endemic	  areas	  before	  providing	  follow-­‐up	  serum	  samples,	  exposures	  to	  natural	  flaviviral	   boosters	   cannot	   be	   excluded,	   yet	   the	   possibility	   of	   such	   boosters	   appears	  only	  marginal	  since	  the	  incidence	  of	  flavivirus	  infections	  in	  travelers	  is	  relatively	  low.	  	  
5.1.2	  Primary	  immunization:	  seroprotection	  against	  non-­vaccine	  strains	  
All	   the	   JE	  vaccines	   currently	   available	   are	  based	  on	   strains	  of	   a	   single	   JEV	  genotype	  (GIII).	  Due	  to	  the	  recent	  emergence	  of	  heterologous	  strains	  and	  genotypes	  in	  Asia33,36,	  we	  wanted	   to	   evaluate	   the	   immunogenicity	   of	   JE-­‐VC	   and	   JE-­‐MB	   against	   test	   strains	  representing	  non-­‐vaccine	  genotypes.	  	  Study	  II	  demonstrated	  that	  a	  primary	  series	  with	  both	  JE-­‐VC	  and	  JE-­‐MB	  has	  the	  potential	   to	   elicit	   neutralizing	   antibodies	   against	   heterologous	   JEV	   strains	   and	  genotypes:	   the	   majority	   of	   subjects	   (83%-­‐97%)	   were	   able	   to	   neutralize	   the	  heterologous	  GI-­‐GIV	  test	  strains	  four	  to	  eight	  weeks	  after	  primary	  immunization	  with	  either	   preparation.	   Even	   though	   protective	   levels	   of	   neutralizing	   antibodies	   were	  elicited	  against	  all	  major	  genotypes,	   the	   relatively	   low	  antibody	   titers	  against	   the	  GI	  test	   strain	   raised	   a	   concern	   regarding	   the	   duration	   of	   cross-­‐protection	   against	   this	  genotype	  currently	  dominating	  in	  large	  parts	  of	  Asia12,14.	  Notably,	  strains	  of	  genotype	  V	  were	  not	  available	  for	  testing.	  However,	  as	  long	  as	  GV	  remains	  such	  a	  rare	  cause	  of	  encephalitis,	  this	  genotype	  appears	  to	  be	  of	  minor	  clinical	  significance.	  Study	  III	  addressed	  the	  longevity	  of	  the	  cross-­‐protective	  immunity	  after	  JE-­‐VC	  primary	  immunization.	  At	  the	  two-­‐year	  follow-­‐up,	  the	  seroprotection	  rates	  against	  the	  non-­‐vaccine	  GII-­‐GIV	   test	   strains	  varied	  between	  87%-­‐93%,	  while	   the	   corresponding	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rates	   against	   GI	   test	   strains	   were	   somewhat	   lower,	   73%.	   These	   data	   suggest	   that	  seroprotection	  might	  wane	  earlier	  against	  GI	  than	  against	  strains	  of	  other	  genotypes.	  This	   finding	   is	   of	   particular	   concern	   since	  GI	  predominates	   in	  many	   areas.	  Whether	  the	  73%	  seroprotection	  rate	  against	  GI	  is	  sufficient	  can	  be	  questioned.	  Previously,	   only	   a	   few	  human	  studies	  have	  evaluated	   the	  antibody	   responses	  elicited	  by	  the	  GIII	  vaccines	  for	  their	  ability	  to	  neutralize	  strains	  of	  heterologous	  JEV	  genotypes133,138,139.	   The	   cross-­‐protective	   capacity	   of	   the	   live	   chimeric	   JE	   vaccine	  has	  been	   evaluated	   in	   two	   studies	   in	   Thai	   children	   and	   in	   Australian	   adults.	   In	   these	  studies,	  70%-­‐97%	  of	  vaccinees	  had	  neutralizing	  antibodies	  against	  GI-­‐GIV	  test	  strains	  one	   month	   after	   primary	   immunization133,138.	   Regarding	   studies	   on	   inactivated	   JE	  vaccines,	   one	   Taiwanese	   study	   explored	   the	   long-­‐term	   seroprotection	   in	   JE-­‐MB–immunized	   children.	   In	   that	   study,	   less	   than	   50%	   of	   5-­‐15	   year-­‐old	   children	   had	  neutralizing	   antibodies	   against	   the	   GI	   test	   strain,	   while	   a	   significantly	   higher	  percentage	   were	   seroprotected	   against	   the	   GIII	   vaccine	   strain	   Nakayama139.	   Hence,	  similarly	   to	   our	   results	   with	   JE-­‐VC,	   the	   study	   suggested	   that	   GIII-­‐vaccine	   immunity	  might	  wane	  earlier	  against	  GI	  than	  against	  the	  vaccine	  genotype.	  	  Studies	   II	   and	   III	  were	   the	   first	   human	   studies	   to	   address	   the	   seroprotection	  provided	  by	   the	   JE-­‐VC	  primary	  series	  against	  strains	  of	  heterologous	   JEV	  genotypes.	  These	   studies	   demonstrated	   satisfactory	   short-­‐term	   seroprotection	   rates	   against	  strains	  of	  all	  major	  JEV	  genotypes.	  The	  somewhat	  lower	  two-­‐year	  seroprotection	  rates	  against	  the	  emerging	  genotype	  call	  for	  further	  studies.	  Future	  research	  should	  address	  the	   long-­‐term	   cross-­‐protection	   in	   larger	   study	   populations,	   and	   at	   different	   time	  points	  in	  order	  to	  determine	  the	  optimal	  timing	  of	  possible	  booster	  doses.	  
5.1.3	  Seroprotection	  after	  heterologous	  and	  homologous	  booster	  
vaccination	  
Prior	  to	  study	  I,	  no	  data	  were	  available	  on	  the	  potential	  of	  the	  new	  SA14-­‐14-­‐2–based	  JE-­‐VC	  vaccine	  to	  boost	  immunity	  after	  a	  primary	  series	  with	  the	  Nakayama-­‐derived	  JE-­‐MB	  vaccines.	  Lack	  of	  data	  had	  resulted	  in	  guidelines,	  e.g.	  from	  the	  CDC,	  recommending	  a	  two-­‐dose	  JE-­‐VC	  primary	  series	  also	  for	  those	  previously	  primed	  with	  JE-­‐MB82.	  	  Study	  I	  demonstrated	  that	  a	  single	  dose	  of	  JE-­‐VC	  efficiently	  boosts	  immunity	  in	  travelers	  with	  a	  history	  of	  JE-­‐MB	  primary	  immunization;	  the	  vast	  majority	  (95%-­‐98%)	  of	   JE-­‐MB–primed	   subjects	   responded	   to	   the	   heterologous	   booster	   vaccine	   with	  seroconversion	   or	   at	   least	   a	   two-­‐fold	   increase	   in	   titers	   of	   neutralizing	   antibodies.	  Furthermore,	   100%	   of	   JE-­‐MB–primed	   subjects	   with	   no	   protection	   at	   baseline	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seroconverted	  after	  receiving	  a	  single	   JE-­‐VC	  dose,	  compared	  to	  a	  corresponding	  rate	  of	   only	   40%	   in	   non-­‐primed	   subjects.	   The	   heterologous	   booster	   responses	   were	  comparable	   to	   those	   seen	   after	   a	   homologous	   booster	   dose.	   The	   results	   of	   the	   first	  study	  support	  the	  use	  of	  a	  single	  JE-­‐VC	  dose	  for	  boosting	  JE-­‐MB	  immunity.	  	  At	   the	   same	   time	   as	   our	   study,	   another	   study	   on	   heterologous	   boosting	  was	  conducted	   in	  US	  military	   personnel	   by	  Woolpert	   and	   colleagues236.	   In	   line	  with	   our	  results,	   this	  study	  also	  demonstrated	  the	  booster	  capacity	  of	   JE-­‐VC	   in	   JE-­‐MB–primed	  subjects.	  Of	  the	  44	  subjects	  with	  a	  history	  of	  ≥3	  JE-­‐MB	  doses,	  68%	  were	  seroprotected	  before	   booster	   vaccination,	   and	   100%	   one	   month	   after	   receiving	   a	   single	   JE-­‐VC	  booster	   dose.	   The	   levels	   of	   neutralizing	   antibodies	   were	   significantly	   higher	   one	  month	   after	   booster	   immunization	   (GMT	   315)	   than	   before	   administration	   of	   the	  booster	  vaccine	  (GMT	  13).	  In	   addition	   to	   examining	   the	   immunogenicity	   of	   a	   single	   JE-­‐VC	   booster	   dose,	  Woolpert	   and	   colleagues	   also	   studied	   the	   effect	   of	   a	   two-­‐dose	   booster	   regimen	   on	  short-­‐term	  immune	  responses.	  In	  that	  study,	  administration	  of	  a	  second	  booster	  dose	  28	   days	   after	   the	   first	   booster	   did	   not	   increase	   the	   seroprotection	   rates	   or	   GMTs	  significantly	   (100%	  seroprotection	  already	  post-­‐booster	  1;	  GMT	  315	  post-­‐booster	  1,	  GMT	   414	   post-­‐booster	   2)236.	   Whether	   the	   two-­‐dose	   booster	   regimen	   could	   have	  beneficial	  effects	  on	  long-­‐term	  immune	  protection	  remains	  as	  yet	  unanswered.	  While	  study	  I	  and	  the	  investigation	  by	  Woolpert	  et	  al.	  were	  the	  first	  to	  address	  the	   boosting	   capacity	   of	   JE-­‐VC	   after	   a	   primary	   series	   with	   JE-­‐MB,	   the	   principle	   of	  heterologous	   boosting	   has	   previously	   been	   evaluated	   with	   heterologous	   JE-­‐MB	  vaccines.	   In	   one	   study,	   Japanese	   high	   school	   students	   from	   a	   JEV	  non-­‐endemic	   area	  received	   a	   homologous	   or	   a	   heterologous	   booster	   with	   either	   a	   Nakayama-­‐	   or	   a	  JaGArO1-­‐based	   JE-­‐MB	   vaccine235.	   Similarly	   to	   our	   study,	   both	   heterologous	   and	  homologous	  booster	  doses	  induced	  high	  levels	  of	  neutralizing	  antibodies	  against	  both	  vaccine	  strains.	  While	  study	  I	  only	  examined	  the	  short-­‐term	  immunity,	  study	  III	  addressed	  the	  long-­‐term	  seroprotection	  after	  heterologous	  booster	   immunization.	   In	   that	  study,	  all	  of	  those	  primed	  with	  JE-­‐MB	  and	  boosted	  with	  the	  heterologous	  JE-­‐VC	  vaccine	  still	  had	  neutralizing	   antibodies	   against	   the	   vaccine	   strains	   two	   years	   after	   the	   booster	  vaccination.	   Moreover,	   the	   majority	   of	   subjects	   (89%-­‐95%)	   also	   had	   neutralizing	  antibodies	  against	  strains	  of	  other	  genotypes,	  including	  the	  emerging	  genotype	  GI,	  at	  the	   two-­‐year	   follow-­‐up.	   The	   two-­‐year	   seroprotection	   rates	   after	   a	   heterologous	  booster	  were	  comparable	  to	  those	  observed	  after	  a	  homologous	  booster.	  Along	  with	  the	   results	   from	   study	   I,	   the	   long-­‐term	   cross-­‐protection	  data	   from	   study	   III	   support	  the	  use	  of	  a	  single	  JE-­‐VC	  dose	  for	  boosting	  JE-­‐MB	  immunity.	  While	  these	  data	  suggest	  that	   JE-­‐MB–primed	   travelers	   are	   still	   seroprotected	   two	   years	   after	   a	   single	   JE-­‐VC	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booster,	  the	  question	  remains	  whether	  the	  second	  JE-­‐VC	  booster	  dose	  could,	  in	  fact,	  be	  delayed	  beyond	   the	   two-­‐year	   limit.	   Further	   longevity	   studies	   are	  needed	   to	   address	  the	  optimal	  timing	  of	  the	  second	  booster	  dose.	  To	  our	  knowledge,	  the	  current	  CDC	  guidelines	  of	  giving	  two	  doses	  of	  JE-­‐VC	  to	  those	  previously	  primed	  with	  JE-­‐MB	  have	  been	  based	  solely	  on	  the	  lack	  of	  any	  data	  on	  heterologous	   boosting	   with	   JE-­‐VC.	   It	   is	   not	   customary	   to	   change	   international	  guidelines	  based	  on	  single	  studies.	  However,	  our	  studies	   I	  and	   III,	  and	  the	  report	  by	  Woolpert	  and	  colleagues	  were	  independently	  conducted,	  yet	  provided	  similar	  results	  supporting	   the	  use	  of	   a	   single	   JE-­‐VC	  dose	   for	  boosting	   JE-­‐MB	   immunity.	  To	  date,	  no	  contradictory	  data	  have	  been	  reported.	  Moreover,	  cross-­‐protection	  between	  the	   two	  vaccine	   strains	   appears	   immunologically	   sound	   in	   terms	   that	   these	   JEV	   strains,	  Nakayama	   and	   SA14-­‐14-­‐2,	   closely	   resemble	   one	   another.	   Some	   countries,	   including	  Finland,	  have	  already	  changed	  their	  recommendations	  to	  state	  that	  only	  one	  dose	  of	  JE-­‐VC	  is	  needed	  for	  boosting	  JE-­‐MB	  immunity.	  	  
5.1.4	  Limitations	  of	  the	  studies	  
Studies	   I-­‐III	   provide	   data	   on	   the	   immunogenicity	   of	   the	   JE	   vaccines	   when	   used	   in	  routine	   circumstances.	   The	   real-­‐life	   setting	   of	   the	   studies	   can,	   on	   one	   hand,	   be	  considered	  as	  a	  strength,	  as	  the	  results	  will	  mostly	  be	  applied	  to	  travelers	   in	  similar	  situations.	  On	  the	  other	  hand,	  the	  study	  design	  introduces	  some	  limitations	  regarding	  generalization	  of	  the	  results	  to	  populations	  with	  different	  background	  characteristics.	  	  The	  non-­‐randomized	  design	  and	  the	  fairly	  small	  group	  sizes	  may	  be	  considered	  as	  the	  main	  limitations	  of	  studies	  I-­‐III.	  The	  research	  questions	  would	  have	  ideally	  been	  addressed	   by	   a	   large,	   randomized,	   double-­‐blind,	   controlled	   trial	   which	   would	   have	  potentially	  provided	  a	  more	  solid	  basis	  to	  validate	  the	  vaccination	  recommendations.	  	  Many	   study	   participants	   received	   other	   vaccines	   concomitantly	   with	   JE	  immunization,	   and	   some	   traveled	   to	   Asia	   before	   providing	   the	   follow-­‐up	   serum	  samples.	  In	  addition,	  some	  volunteers	  had	  previously	  been	  immunized	  against	  TBE	  or	  YF.	   All	   these	   factors	   may	   be	   considered	   as	   additional	   limitations	   of	   the	   studies.	  Although	   relatively	   unlikely,	   the	   possibility	   of	   natural	   flaviviral	   boosters	   cannot	   be	  excluded	  in	  subjects	  who	  visited	  endemic	  areas	  in-­‐between	  serum	  samples.	  Regarding	  the	   history	   of	   immunizations	   against	   other	   flaviviruses,	   no	   clear	   differences	   were	  observed	  in	  the	  immune	  responses	  between	  subjects	  with	  or	  without	  preceding	  TBE	  or	  YF	  vaccinations.	  Yet,	   the	  studies	  were	  not	  designed	   to	  address	   the	  effect	  of	  other	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flavivirus	   vaccines	   on	   JE	   vaccine	   immunity,	   and	   the	   small	   number	   of	   participants	  limits	  firm	  conclusions	  based	  on	  these	  data.	  	  
5.2	  Study	  IV:	  Viremia	  and	  NS1	  antigenemia	  in	  travelers’	  dengue	  
5.2.1	  Kinetics	  of	  viremia	  and	  NS1	  antigenemia	  
Study	   IV	   examined	   the	   kinetics	   of	   diagnostic	   markers	   and	   associations	   between	  virologic	   (viremia,	   NS1	   antigenemia)	   and	   clinical	   parameters	   in	   travel-­‐associated	  dengue	  infections.	  	  Kinetics	   analyses	   confirmed	   the	   high	   sensitivity	   of	   RT-­‐PCR	   and	   NS1	   antigen	  detection	  early	  in	  the	  illness	  course;	  the	  vast	  majority	  of	  patients	  were	  positive	  with	  both	   methods	   during	   the	   first	   days	   of	   illness,	   in	   line	   with	   results	   from	   previous	  studies188,189,237.	   Viremia	   and	  NS1	   antigenemia	   lasted	   longer	   in	   the	   traveler	   patients	  than	  usually	   reported	   in	   endemic	   settings165,174,190.	  One	  possible	   explanation	   for	   the	  long	   detection	   span	   of	   DENV	   RNA	   and	   NS1	   antigen	   can	   be	   the	   high	   percentage	   of	  primary	   infections	  among	  the	  study	  population,	  as	   the	  clearance	  of	  viremia	  and	  NS1	  antigenemia	   has	   been	   suggested	   to	   be	   slower	   in	   primary	   than	   in	   secondary	  infections165.	  NS1	  antigen	  was	  detected	  in	  serum	  samples	  for	  a	  significantly	  longer	  period	  of	  time	   than	   DENV	   RNA,	   possibly	   due	   to	   a	   slower	   rate	   of	   NS1	   clearance	   from	   plasma	  compared	   to	   that	   of	   viral	   RNA.	   The	   early	   appearance	   and	   long	   duration	   of	   NS1	  antigenemia,	  as	  well	  as	  the	  high	  specificity,	  rapidity,	  and	  easy	  performance	  of	  the	  test	  make	  the	  detection	  of	  NS1	  a	  feasible	  tool	  in	  the	  diagnostics	  of	  traveler’s	  dengue.	  In	   addition	   to	   individual	   diagnostic	   markers,	   we	   also	   examined	   different	  combinations	  of	  two	  diagnostic	  tests.	  These	  analyses	  supported	  a	  combined	  approach	  with	  serologic	  testing	  and	  DENV	  RNA	  or	  NS1	  detection	  for	  efficient	  diagnostics,	  in	  line	  with	  results	  from	  other	  studies190,233,238.	  
5.2.2	  Associations	  between	  virologic	  markers	  and	  clinical	  parameters	  
In	   the	  Finnish	  traveler	  patients,	  several	  significant	  associations	  were	   found	  between	  the	  early	  relative	   levels	  of	  virologic	  markers	  and	  clinical	  parameters.	  High	  viral	   load	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predicted	   deeper	   thrombocytopenia	   during	   the	   illness	   course,	   as	   well	   as	   greater	  likelihood	   and	   length	   of	   hospitalization.	   The	   early	   magnitude	   of	   NS1	   antigenemia	  correlated	   negatively	  with	   platelet	   counts,	   and	   positively	  with	   hematocrit	   and	   liver	  transaminase	   levels.	   Notably,	   the	   day	   of	   illness	   was	   controlled	   in	   the	   statistical	  analyses	  to	  avoid	  a	  potential	  confounding	  effect	  on	  the	  observed	  associations.	  In	  endemic	  patient	  populations,	  high	  viremia	  and	  NS1	  antigenemia	  have	  been	  linked	   to	   a	   severe	   illness	   course165,199,200,205.	   However,	   some	   studies	   have	   reported	  contradictory	  results190,196.	  Based	  on	  the	  observed	  associations	  between	  virologic	  and	  clinical	   parameters	   (e.g.	   hematocrit	   and	   platelet	   count),	   this	   study	   suggests	   that	  viremia	   and	  NS1	   antigenemia	  may	   serve	   as	   predictors	   of	   the	   clinical	   picture	   also	   in	  traveler	  patients.	  
5.2.3	  Limitations	  of	  the	  study	  








This	  thesis	  explores	  the	  immunogenicity	  of	  inactivated	  Japanese	  encephalitis	  vaccines	  and	  the	  diagnostics	  of	  dengue	  in	  Northern	  European	  travelers.	  	  The	  first	  study	  confirmed	  the	  immunogenicity	  of	   JE-­‐VC	  and	  JE-­‐MB	  vaccines	  in	  priming,	  and	  showed	  that	  a	  single	  dose	  of	  JE-­‐VC	  was	  able	  to	  efficiently	  boost	  immunity	  in	   adult	   travelers	   primed	   with	   a	   heterologous	   preparation,	   the	   traditional	   JE-­‐MB	  vaccine.	   Even	   though	   no	   specific	   data	   were	   available	   prior	   to	   the	   study,	   a	   cross-­‐reactive	   immunological	  memory	   between	   JE-­‐MB	   and	   JE-­‐VC	  was	   expected,	   since	   the	  strains	  in	  the	  vaccines	  closely	  resemble	  one	  another	  genetically.	  Previously,	  as	  no	  data	  were	  available	  on	   the	  use	  of	   JE-­‐VC	  as	   a	  heterologous	  booster,	   the	  health	  authorities	  refrained	   from	   recommending	   the	   new	   vaccine	   for	   boosting	   JE-­‐MB	   immunity	   but,	  instead,	  recommended	  a	  two-­‐dose	  primary	  series	  for	  those	  previously	  primed	  with	  JE-­‐MB.	   The	   demonstration	   of	   heterologous	   booster	   capacity	   for	   JE-­‐VC	   has	   practical	  clinical	  consequences,	  since	  the	  results	  may	  call	   for	  vaccination	  recommendations	  to	  be	   re-­‐visited.	   In	   Finland,	   for	   instance,	   the	   guidelines	   have	   already	   been	   updated	  accordingly.	  In	   addition	   to	   providing	   data	   on	   heterologous	   boosting,	   the	   first	   study	   also	  demonstrated	  differences	  in	  the	  titers	  of	  neutralizing	  antibodies	  depending	  on	  the	  JEV	  test	   strain	  used	   in	   the	  assay.	  The	  neutralizing	  capacity	  was	   found	   to	  be	  significantly	  higher	   against	   the	   homologous	   than	   the	   heterologous	   target	   strain.	   This	   finding	  stresses	   the	   point	   that	   comparing	   the	   immunogenicity	   of	   heterologous	   vaccines	  requires	   testing	  with	  all	   relevant	   strains	   to	  avoid	  a	  bias	   favoring	  either	  vaccine	  –	   in	  contrast	  to	  what	  has	  been	  done	  in	  many	  previous	  JE	  vaccine	  immunogenicity	  studies.	  The	  second	  study	  explored	  the	  seroprotection	  against	  non-­‐vaccine	  strains	  and	  genotypes	   after	   primary	   immunization	   with	   JE-­‐VC	   and	   JE-­‐MB.	   This	   study	  demonstrated	   that	   a	   primary	   series	   with	   both	   vaccines	   has	   the	   potential	   to	   elicit	  neutralizing	  antibodies	  against	  heterologous	  strains	  of	  JEV	  genotypes	  GI,	  GII,	  and	  GIV,	  not	  only	  against	   those	   representing	   the	  vaccine	  genotype,	  GIII.	  This	   implies	   that	   the	  current	  JE-­‐VC	  and	  JE-­‐MB	  vaccines	  are	  expected	  to	  confer	  protection	  against	  all	  major	  JEV	  genotypes	  circulating.	  The	   third	   study	   addressed	   the	   long-­‐term	   seroprotection	   provided	   by	   JE-­‐VC	  primary	  and	  booster	  vaccinations.	  After	  primary	  series	  with	  JE-­‐VC,	  the	  seroprotection	  seemed	  to	  wane	  earlier	  against	  GI	  strains	  than	  against	  strains	  of	  other	  genotypes.	  This	  finding	   is	   of	   particular	   concern,	   since	   GI	   strains	   currently	   predominate	   in	   many	  endemic	   areas.	   The	   long-­‐term	   cross-­‐protection	   after	   JE-­‐VC	   primary	   immunization	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